<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cell Mol Life Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Cell. Mol. Life Sci</journal-id>
<journal-title-group>
<journal-title>Cellular and Molecular Life Sciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">1420-682X</issn>
<issn pub-type="epub">1420-9071</issn>
<publisher>
<publisher-name>Springer International Publishing</publisher-name>
<publisher-loc>Cham</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31172215</article-id>
<article-id pub-id-type="pmc">6647627</article-id>
<article-id pub-id-type="publisher-id">3180</article-id>
<article-id pub-id-type="doi">10.1007/s00018-019-03180-8</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>MMPs in learning and memory and neuropsychiatric disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Beroun</surname>
<given-names>Anna</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mitra</surname>
<given-names>Shiladitya</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Michaluk</surname>
<given-names>Piotr</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pijet</surname>
<given-names>Barbara</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stefaniuk</surname>
<given-names>Marzena</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kaczmarek</surname>
<given-names>Leszek</given-names>
</name>
<address>
<phone>+4822659 3001</phone>
<email>l.kaczmarek@nencki.gov.pl</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1943 2944</institution-id><institution-id institution-id-type="GRID">grid.419305.a</institution-id><institution>BRAINCITY, Nencki Institute, </institution></institution-wrap>Pasteura 3, 02-093 Warsaw, Poland </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>6</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>6</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2019</year>
</pub-date>
<volume>76</volume>
<issue>16</issue>
<fpage>3207</fpage>
<lpage>3228</lpage>
<history>
<date date-type="received">
<day>27</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>27</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>5</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Matrix metalloproteinases (MMPs) are a group of over twenty proteases, operating chiefly extracellularly to cleave components of the extracellular matrix, cell adhesion molecules as well as cytokines and growth factors. By virtue of their expression and activity patterns in animal models and clinical investigations, as well as functional studies with gene knockouts and enzyme inhibitors, MMPs have been demonstrated to play a paramount role in many physiological and pathological processes in the brain. In particular, they have been shown to influence learning and memory processes, as well as major neuropsychiatric disorders such as schizophrenia, various kinds of addiction, epilepsy, fragile X syndrome, and depression. A possible link connecting all those conditions is either physiological or aberrant synaptic plasticity where some MMPs, e.g., MMP-9, have been demonstrated to contribute to the structural and functional reorganization of excitatory synapses that are located on dendritic spines. Another common theme linking the aforementioned pathological conditions is neuroinflammation and MMPs have also been shown to be important mediators of immune responses.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Behavioral training</kwd>
<kwd>Schizophrenia</kwd>
<kwd>Autism</kwd>
<kwd>Epilepsy</kwd>
<kwd>Addiction</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>Foundation for Polish Science</institution>
</funding-source>
<award-id>BRAINCITY</award-id>
<principal-award-recipient>
<name>
<surname>Kaczmarek</surname>
<given-names>Leszek</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Nature Switzerland AG 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction to MMPs in the brain</title>
<p id="Par49">Extracellular matrix (ECM) in the brain has emerged as an important reservoir of signaling molecules, which can influence synaptic plasticity, synaptogenesis, neurite outgrowth and other processes occurring in central nervous system. Many suggest now that “tetrapartite synapse” is a functional unit of the brain, where ECM plays equally important roles to pre-, post-synaptic terminals and glial cells’ invaginations [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Matrix metalloproteinases (MMPs) are among the major modulators of ECM, providing precise proteolysis of its components, in addition to performing limited cleavage of cell adhesion molecules (CAMs), neurotrophins and cytokines [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. MMPs make up a family of over 20 proteins in humans and rodents (predominantly secreted, but six are membrane-bound), each encoded by a different gene. MMPs are a part of bigger, metzincin group of proteases, which all have Zn<sup>2+</sup> and the conserved methionine residue in their active site [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p id="Par50">Based on their domain structure, MMPs are subdivided into eight groups, but all are composed of (starting from N-terminus): a signal peptide, propeptide, catalytic domain and in most cases hinge region and hemopexin domain. The signal peptide is removed after the protein enters the endoplasmic reticulum. MMPs are expressed as inactive zymogens, where the propeptide has conserved cysteine residue binding Zn<sup>2+</sup> in the active center of the enzyme. Activation occurs when the interaction between cysteine and Zn<sup>2+</sup> is disrupted, which can be achieved by cleaving the propeptide off (by other proteases), as well as by other means, such as S-nitrosylation, detergents or sulphates [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The catalytic domain of all MMPs has a highly conserved Zn<sup>2+</sup> binding motif—HExGHxxGxxH (where x is any amino acid) and a distinct β-turn (usually ALMYP). That is why all MMPs have distinguishable, but often overlapping, substrate specificities. Moreover, the catalytic domain of MMPs requires binding of Ca<sup>2+</sup> ions which are required for the stabilization of its active state [<xref ref-type="bibr" rid="CR7">7</xref>]. Gelatinases (MMP-2 and -9) have additional fibronectin type II inserts, which are required for collagen and elastin binding and cleavage.</p>
<p id="Par51">Most of MMPs (except of MMP-7, MMP-26 and MMP-23) have hinge region and hemopexin domain, which is responsible for interaction with substrates, dimerization and binding of one of four endogenous tissue inhibitors of metalloproteinases (TIMPs). MMP-23 instead of hemopexin domain has unique cysteine-rich, proline-rich and IL-1 type II receptor-like domains. MMP-14, MMP-15, MMP-16, and MMP-24 have also a transmembrane domain which anchors them to the cell membrane whereas MMP-17, and MMP-25 have on their C-terminus a glycophosphatidyl inositol membrane anchoring signal [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p id="Par52">Since excessive activity of MMPs might be detrimental to the tissue (as it happens under some pathological conditions), the enzyme gene expression, mRNA maturation, distribution and survival, as well as protein release and activation are all strictly regulated. This can be best described in the example of one of the most studied MMP, MMP-9 [<xref ref-type="bibr" rid="CR8">8</xref>]. MMP-9 transcription is activity regulated by inducible transcription factors, such as AP-1 [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], then MMP-9 mRNA transport, survival and translation are also activity regulated, as it has been demonstrated for neurons [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR13">13</xref>]. MMP-9 is present within cells in vesicles distributed along microtubules and microfilaments and is secreted in a Golgi-dependent pathway in 160–200 nm vesicles [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR16">16</xref>]. Notably, MMP-9 is often found in the same secretory vesicles as its inhibitor, TIMP-1 and although secreted upon stimulation, it is thought to act very focally and can be concentrated at the cell membrane by binding to cell adhesion molecules such as the hyaluronian receptor CD44 [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] or integrins [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
<p id="Par53">The activation of proMMP-9 occurs extracellularly after its release and is controlled by a cascade of steps involving other proteases, inhibitors and receptors. For example, serine proteases: tissue plasminogen activator (tPA) or urokinase plasminogen activator (uPA), which can be docked to the membrane by its receptor, uPAR, activate the conversion of plasminogen to plasmin, which in turn can activate proMMP-9 [<xref ref-type="bibr" rid="CR20">20</xref>]. Additionally, some MMPs such as MMP-11 or MMP-28 and all membrane-type MMPs (MT-MMPs) have also a furin-like recognition motif in their propeptide and can be thus activated inside the cell before secretion or exposure to cell surface, and activate other secreted MMPs [<xref ref-type="bibr" rid="CR21">21</xref>]. Once activated, MMP-9 can be inhibited, particularly by TIMP-1, but also by other TIMPs [<xref ref-type="bibr" rid="CR22">22</xref>]. This is because, similarly to redundancy in MMPs substrate specificity, there is a significant overlap in the affinity of TIMPs to different MMPs [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
<p id="Par54">TIMP-1 can inhibit MMPs directly by binding through its N-terminal domain to the catalytic site of the enzyme [<xref ref-type="bibr" rid="CR23">23</xref>]. Interestingly, inhibition of MMP-9 can be also achieved by binding TIMP-1 C-terminus to the hemopexin domain of MMP-9, thus blocking its interaction with substrate or membrane docking proteins [<xref ref-type="bibr" rid="CR24">24</xref>]. MMP-9 and TIMP-1 share the same release kinetics [<xref ref-type="bibr" rid="CR25">25</xref>] and it has been shown that those two proteins can be co-released even from a single vesicle [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Moreover, it has been proposed by Ogata and co-workers [<xref ref-type="bibr" rid="CR27">27</xref>] that TIMP-1 bound to MMP-9 via the hemopexin domain is also important during activation of the gelatinase by other MMPs, like MMP-3. Finally, activated MMP-9 binds through its hemopexin domain to low-density lipoprotein receptor-related protein, which is an endocytic receptor for this and many other proteins, and after endocytosis leads to the destruction of MMP-9 [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
<p id="Par55">All the regulatory mechanisms, such as secretion, interaction with membrane receptors, internalization and TIMP-dependent inhibition, are to limit spatially and temporarily MMP’s activity outside the cell and prevent excessive, potentially pathological activity. An interesting example of physiological, tight control by TIMP-1 over MMP-9 has been recently published by Magnowska et al. [<xref ref-type="bibr" rid="CR29">29</xref>], where both proteolytic activity of MMP-9 and its following inhibition by TIMP-1 were discovered to be necessary for synaptic plasticity (see below). Interestingly, activation of MMP-9 in the brain tissue can be achieved by the degradation of TIMP-1 by cathepsin B, a lysosomal enzyme, which upon stimulation can be released to extracellular space and activate MMP-9 [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Another example of MMP activating cascade is that of MMP-2, as it requires the formation of tertiary complex with TIMP-2 and MT1-MMP [<xref ref-type="bibr" rid="CR32">32</xref>]. TIMP-2 forms a link between dimerized MT1-MMP and the hemopexin domain of pro-MMP-2. This leads to cleavage of MMP-2 propeptide by MT1-MMP and thus its activation.</p>
<p id="Par56">As already mentioned, MMPs are inhibited by four endogenous inhibitors, TIMP-1 to TIMP-4. They are all soluble and share a common structure, but their role is very diverse. For example, TIMP-1 can act independently to its inhibitory activity as a growth factor suppressor [<xref ref-type="bibr" rid="CR33">33</xref>] or a cytokine [<xref ref-type="bibr" rid="CR34">34</xref>]. The cytokine effect of TIMP-1, which results in inhibition of neurite outgrowth and increase in growth cone volume, is mediated through its internalization by LRP-1 [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p>
</sec>
<sec id="Sec2">
<title>Expression in the brain</title>
<p id="Par57">Among the MMPs, many have been shown to be expressed in the brain, namely: MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-16, MMP-17, MMP-24 and MMP-28. Notably, a number of those are expressed in the brain only under very particular physiological and/or pathological circumstances.</p>
<p id="Par58">MMP-1 (collagenase 1) expression in the brain has often remained undetected [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. However, recent studies have shown MMP-1 immunoreactivity in the olfactory lobe, entorhinal cortex, pontine nuclei, and periaqueductal gray, but not in the hippocampus [<xref ref-type="bibr" rid="CR39">39</xref>]. Moreover, MMP-1 protein level was increased at 4 h following systemic kainate administration [<xref ref-type="bibr" rid="CR39">39</xref>] or after ischemic stroke [<xref ref-type="bibr" rid="CR40">40</xref>], and was shown to be present in the brains of Alzheimer’s disease patients [<xref ref-type="bibr" rid="CR41">41</xref>]. MMP-1 seems to be mostly expressed by glia [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>], but there are also reports indicating its presence in neurons [<xref ref-type="bibr" rid="CR39">39</xref>]. MMP-1 was also shown to enhance proliferation and increased differentiation towards neurons of hippocampal neural progenitor cells [<xref ref-type="bibr" rid="CR44">44</xref>]. Moreover, MMP-1 overexpression in transgenic mice under GFAP gene promoter enhances dendritic complexity and causes deficits in learning and memory [<xref ref-type="bibr" rid="CR42">42</xref>]. Literature suggests that MMP-1 in the brain acts mainly through activating protease activated receptor 1 (PAR1) [<xref ref-type="bibr" rid="CR44">44</xref>], and thus increasing cytoplasmic Ca<sup>2+</sup> concentration [<xref ref-type="bibr" rid="CR42">42</xref>], as it was proven also in platelets [<xref ref-type="bibr" rid="CR45">45</xref>]. Interestingly, PAR1 was shown to be cleaved and activated by another collagenase which is also expressed in the brain, MMP-13, however, this relationship was studied in cardiac fibroblasts and cardiomyocytes [<xref ref-type="bibr" rid="CR45">45</xref>].</p>
<p id="Par59">MMP-2 (gelatinase A) is one of the two gelatinases most extensively studied in the brain. It is constitutively expressed mainly by astrocytes [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>], however, many studies find it to be localized also in some cortical, and cerebellar neurons, as well as in the hippocampus and nucleus accumbens (NAc) [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR48">48</xref>–<xref ref-type="bibr" rid="CR51">51</xref>]. MMP-2, like most of the MMPs in the brain, is expressed at much higher level during early postnatal development than during adulthood, reaching peak around day 4 after birth [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. MMP-2 expression can be induced under various pathological conditions (see below). In particular, reactive astrocytes show increased expression of MMP-2 [<xref ref-type="bibr" rid="CR53">53</xref>]. MMP-2 in astrocytes is localized at the leading edge of processes, where it regulates actin cytoskeleton and thus affects cell migration [<xref ref-type="bibr" rid="CR54">54</xref>].</p>
<p id="Par60">MMP-3 (stromelysin 1) is, as many other MMPs, expressed during development in the central nervous system. Around embryonic day 15, it is expressed in most brain areas in rat, and in mouse it is found in neurons of the ventricular zone. In late prenatal period, MMP-3 is also expressed in mature oligodendrocytes [<xref ref-type="bibr" rid="CR55">55</xref>]. Until postnatal day 10, MMP-3 is expressed by most cells of the cerebellar cortex, striatum and hippocampus and can be found in both neuronal and glial cells [<xref ref-type="bibr" rid="CR55">55</xref>–<xref ref-type="bibr" rid="CR57">57</xref>]. MMP-3 is also expressed during postnatal brain development in cerebellum, specifically in Purkinje cell somata and dendrites as well as in some granule cells [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. In the adult brain, MMP-3 expression level is either very low or negligible [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR59">59</xref>], but some studies report its expression in the hippocampus, especially during learning paradigms [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. A recent study of Wiera et al. [<xref ref-type="bibr" rid="CR57">57</xref>] shows that in the stratum radiatum of hippocampus, MMP-3 seems to be mainly expressed by astrocytes in a sparse punctate manner. MMP-3 has a very broad range of substrates in the brain. It was shown, for example, to cleave almost all components of perineuronal nets [<xref ref-type="bibr" rid="CR53">53</xref>]. MMP-3 is upregulated in many brain pathologies, disrupting blood–brain barrier, causing neuroinflammation and apoptosis. In such conditions, it is expressed by injured neurons, oligodendrocytes, astrocytes and reactive microglia or invading macrophages [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Induction of MMP-3 expression depends on binding of NFκB to its gene promoter upon the release of inflammatory mediators, e.g., interleukin-1β caused by ischemia, traumatic brain injury (TBI) or infections [<xref ref-type="bibr" rid="CR64">64</xref>]. In addition, MMP-3 acts itself as a signaling molecule and creates positive feedback for inflammatory response, as it causes activation of microglia and synthesis of cytokines, e.g., tumor necrosis factor-α, interleukin-1β, or interleukin-6 [<xref ref-type="bibr" rid="CR65">65</xref>]. However MMP-3 was also shown to have beneficial effects during pathological states as it can cleave Fas ligand [<xref ref-type="bibr" rid="CR66">66</xref>], can promote synaptogenesis [<xref ref-type="bibr" rid="CR67">67</xref>] and is involved in remyelination [<xref ref-type="bibr" rid="CR68">68</xref>].</p>
<p id="Par61">MMP-7 (matrilysin) expression during development, as well as in the normal adult brain, is often described as negligible [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR69">69</xref>–<xref ref-type="bibr" rid="CR71">71</xref>]. Most reports that detect MMP-7 in normal brain conditions point to glia (most often microglia) as MMP-7 expressing cells [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]; although the issue of MMP-7 source in the brain has often not been addressed in various studies. Interestingly, Le and Friedman [<xref ref-type="bibr" rid="CR74">74</xref>] reported a high level of MMP-7 in hippocampal neurons, which dropped after seizures induced with kainic acid. MMP-7 is, though, strongly upregulated during such pathological conditions in the brain as multiple sclerosis [<xref ref-type="bibr" rid="CR73">73</xref>], experimental autoimmune encephalomyelitis [<xref ref-type="bibr" rid="CR75">75</xref>], HIV dementia [<xref ref-type="bibr" rid="CR76">76</xref>] or brain tumors [<xref ref-type="bibr" rid="CR71">71</xref>]. Among the substrates of MMP-7 in the brain, the most prominent are pro-nerve growth factor (pro-NGF) [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR77">77</xref>], SNAP-25 [<xref ref-type="bibr" rid="CR78">78</xref>], the NR1 subunit of NMDA receptor [<xref ref-type="bibr" rid="CR79">79</xref>] or myelin-associated glycoprotein [<xref ref-type="bibr" rid="CR80">80</xref>].</p>
<p id="Par62">MMP-9 (gelatinase B) is the most studied MMP in the brain, with its expression in naïve brain kept on a very low level. It is found in hippocampus, cerebellum and cerebral cortex [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>] and is predominantly expressed by neurons, but also by glia [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. MMP-9 expression is tightly regulated on different levels (see above) and it peaks during early development [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Even though MMP-9 levels in the adult brain are low, they are upregulated during neuronal increased activity/plasticity but also, as so many other MMPs in pathological situations (see below and for recent reviews: [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]). Most interestingly, MMP-9 activity, as well as its mRNA are present in the vicinity of synapses [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR82">82</xref>–<xref ref-type="bibr" rid="CR84">84</xref>].</p>
<p id="Par63">MMP-14 (MT1-MMP) is most often studied in the brain in the context of gliomas, where it is highly expressed along other MMPs. Under pathological and inflammatory conditions, it has been found expressed by microglia [<xref ref-type="bibr" rid="CR85">85</xref>]. MT1-MMP is, however, expressed on a low level in the normal adult brain [<xref ref-type="bibr" rid="CR37">37</xref>]. MT1-MMP in the hippocampus is predominantly localized in neuronal cell layer [<xref ref-type="bibr" rid="CR86">86</xref>] and expression of MT1-MMP is elevated upon BDNF treatment in mixed neuronal cultures [<xref ref-type="bibr" rid="CR87">87</xref>]. In retina, it is expressed in retinal ganglion cells as well as in Müller glia [<xref ref-type="bibr" rid="CR88">88</xref>]. Interestingly, MT1-MMP expression increases in female hippocampus upon the presentation of novel odor [<xref ref-type="bibr" rid="CR89">89</xref>].</p>
<p id="Par64">MMP-24 (MT5-MMP) is expressed at relatively high levels in the adult brain, particularly in the cerebellum, but also hippocampus and olfactory bulb [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. It can be found predominantly in neurons and its expression is increased during development regulating axonal growth and dendritic tree formation of Purkinje cells [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>].</p>
</sec>
<sec id="Sec3">
<title>Synaptic plasticity, learning and memory: MMPs expression and function</title>
<p id="Par65">Brain plasticity refers to the capacity for structural and functional reorganization of the neural networks in response to external challenges. Beside learning and memory, which allow for adaptation to the changing environment, neuroplasticity is necessary to recover after disorders and injuries. Brain plasticity is manifested at many levels in the nervous system, ranging from molecular events, such as changes in gene expression, protein availability and function, to cellular physiology, to behavior. At the cellular level, the plasticity is supported by dynamic modifications in neural connectivity and excitability that are driven by molecular changes in synapses, entire neurons and glial cells.</p>
<p id="Par66">Synapses are particularly prone to dynamic alterations, and thus believed to play a major role in the plasticity. Aberrant synaptic plasticity leads to many pathological conditions, e.g., epileptogenesis, drug addiction, autism spectrum disorders, schizophrenia or depression. Compensatory brain plasticity may reduce the detrimental effects of such pathologies as multiple sclerosis, Parkinson’s disease, cognitive deterioration or Alzheimer’s disease. Induction and maintenance of activity-dependent synaptic plasticity adaptations require a temporal and spatial control of a complex sequence of events that result in the modification of pre- and postsynaptic content, as well as remodeling of the entire tetra-synapse morphology.</p>
<p id="Par67">Excitatory synapses that are particularly plastic, are predominantly located on small dendritic protrusions called spines, whose morphology can be taken as a proxy for the synaptic efficacy [<xref ref-type="bibr" rid="CR93">93</xref>]. Small dendritic spines often harbor silent synapses, equipped with a limited number of NMDA receptors for glutamate and virtually missing AMPA receptors (AMPAR) for this excitatory neurotransmitter. Increased synaptic efficacy that may produce neuronal depolarization associates with the accumulation of AMPAR (and thus enhanced glutamate responsiveness) that in turn correlates with increased spine volume and enlargement of the dendritic spine head, producing spines with a mushroom shape.</p>
<p id="Par68">MMPs have repeatedly been implicated in synaptic plasticity thanks to their capacity to act in a tightly controlled, short temporal window, targeting extracellular matrix, cell adhesion molecules, synaptic receptors, neurotrophins and other proteins implicated in synaptic efficacy and remodeling. Studies with broad spectrum MMPs inhibitors have demonstrated impairments in various short- and long-term plasticity models including paired pulse and theta burst facilitation, maintenance of long-term potentiation (LTP), induction and magnitude of long-term depression (LTD) in the hippocampus [<xref ref-type="bibr" rid="CR94">94</xref>–<xref ref-type="bibr" rid="CR96">96</xref>], as well as ocular dominance plasticity in the visual cortex and barrel cortex plasticity, resulting from sensory deprivation [<xref ref-type="bibr" rid="CR97">97</xref>–<xref ref-type="bibr" rid="CR99">99</xref>].</p>
<p id="Par69">Recent studies have shed light on the role of MMPs in synaptic plasticity. In this regard, the best studied involvement of metalloproteinase function in synaptic plasticity processes concerns the activity of MMP-9. This issue has been covered by extensive reviews [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR100">100</xref>–<xref ref-type="bibr" rid="CR103">103</xref>], so it will be only briefly presented here.</p>
<p id="Par70">MMP-9 is released from the postsynaptic compartment of excitatory synapses in an activity-dependent manner [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Upon activation, MMP-9 cleaves (among others) such synaptic cell-adhesion molecules as: β-dystroglycan [<xref ref-type="bibr" rid="CR104">104</xref>], neuroligin-1 [<xref ref-type="bibr" rid="CR105">105</xref>], nectin-3 [<xref ref-type="bibr" rid="CR106">106</xref>], intercellular adhesion molecule-5 (ICAM-5) [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR108">108</xref>], synaptic cell adhesion molecule-2 and collapsin response mediator protein-2 [<xref ref-type="bibr" rid="CR109">109</xref>], affecting NMDA receptors mobility and function at the synapse [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. Chemical LTP experiments on dissociated and organotypic hippocampal cultures revealed MMP-9-dependent spine enlargement, accumulation of AMPA receptors in the synapse and increase in the spike count and bursts frequency [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR112">112</xref>–<xref ref-type="bibr" rid="CR115">115</xref>]. Transient function of MMP-9 is a requirement for maintenance of the late phase, NMDA-dependent LTP at various pathways in the hippocampus [<xref ref-type="bibr" rid="CR116">116</xref>–<xref ref-type="bibr" rid="CR119">119</xref>], prefrontal cortex (PFC) [<xref ref-type="bibr" rid="CR120">120</xref>], as well as basal and central nuclei of the amygdalar complex [<xref ref-type="bibr" rid="CR121">121</xref>]. Furthermore, Dziembowska et al. [<xref ref-type="bibr" rid="CR11">11</xref>] reported increases in MMP-9 mRNA levels in the hippocampal dentate gyrus of rats with LTP evoked therein by the perforant path stimulation.</p>
<p id="Par71">The increase of limited MMP-9 activity at the synapse has a profound impact on synaptic morphology. It was reported that activation of this metalloproteinase during LTP induction leads to the enlargement of dendritic spines [<xref ref-type="bibr" rid="CR118">118</xref>]. This, actually, is a two-step process that begins with the MMP-9-mediated elongation of dendritic spines into apparently more immature, filopodium-like shape [<xref ref-type="bibr" rid="CR122">122</xref>–<xref ref-type="bibr" rid="CR124">124</xref>]. Then, only upon inhibition of the proteolytic activity, which in neurons might be mediated via specific inhibitor TIMP-1 [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR125">125</xref>], dendritic spines assume larger, mushroom-like shape [<xref ref-type="bibr" rid="CR29">29</xref>].</p>
<p id="Par72">As far as learning and memory are concerned, MMP-9 activity was reported to be increased after Morris water maze, head-shake response, passive avoidance and appetitive learning [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]. Importantly, in addition to the functional role of MMP-9 in activity-dependent synaptic remodeling, blocking the enzyme has dramatic consequences on learning processes in vivo. Using either pharmacological inhibition or genetic ablation, it was demonstrated that MMP-9 activity was necessary for hippocampus-dependent learning, as shown in Morris water maze, contextual fear conditioning and reconsolidation of fear memory [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>], as well as amygdala-dependent positive reinforcement conditioning in sucrose preference task [<xref ref-type="bibr" rid="CR126">126</xref>]. On the other hand, fear conditioning to an auditory cue, as well as avoidance learning of an exposure to an air-puff or a bitter taste in the Intellicages, remained undisturbed in MMP-9 KO mice [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]. Of note, LTP to lateral nucleus of the amygdala is believed to support the aversive learning, such as aforementioned fear conditioning to an auditory cue [<xref ref-type="bibr" rid="CR121">121</xref>]. Therefore, lack of MMP-9 requirement in the aversive learning might be explained by the fact that the enzyme is not obligatory for the lateral amygdala synaptic plasticity and LTP.</p>
<p id="Par73">Interestingly, MMP-9 has also been considered as a player in human cognition. In the study of Bach et al. [<xref ref-type="bibr" rid="CR129">129</xref>], blocking the activity of MMP-9 by administration of its inhibitor doxycycline 3.5 h prior to the fear conditioning procedure, reduced the fear response in human subjects measured 1 week after the test. This might suggest that lower MMP-9 activity during fear acquisition phase attenuated the formation of the fear memory. Moreover, reduced mRNA and protein levels of MMP-2, MMP-9 and TIMP-2 were observed in patients diagnosed with depression and displaying lower performance in cognitive tasks, as compared to healthy subjects [<xref ref-type="bibr" rid="CR130">130</xref>]. Furthermore, within the healthy control group, there was a positive correlation between MMP-2 (protein level), MMP-9 and TIMP-2 (mRNA levels) and performance in cognitive tasks: visuospatial performance, working memory tasks, auditory-verbal memory, the effectiveness of learning processes and verbal fluency [<xref ref-type="bibr" rid="CR130">130</xref>]. Similar positive correlation between MMP-9 serum level and decision-making abilities was observed in bulimia nervosa patients [<xref ref-type="bibr" rid="CR131">131</xref>]. Another report on MMP-9 involvement in cognition comes from a study on male bipolar patients. Those subjects carrying a <italic>MMP9</italic> gene polymorphism −1562C/C, apparently characterized with lower promoter activity, performed better in cognitive tests than people with other genotypes [<xref ref-type="bibr" rid="CR132">132</xref>]. It should be, however, noted that recent study by Gregory et al. [<xref ref-type="bibr" rid="CR133">133</xref>] has questioned the role of this gene polymorphism in regulating MMP-9 expression in the brain and, furthermore, has demonstrated the gene polymorphism affects the brain structure and function that obviously may contribute to cognition.</p>
<p id="Par74">MMP-3 role in learning and memory is best described in hippocampus-dependent learning tasks. In a spatial memory test—the Morris water maze—it was reported that MMP-3 mRNA and protein levels were elevated during the acquisition phase, while pharmacological inhibition of MMP-3 activity disrupted this learning process [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]. The increase of MMP-3 level in this spatial learning task was prevented by the blocking of the NMDA receptor with the MK-801 antagonist [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]. Similarly to spatial learning, a passive avoidance test revealed an increase of MMP-3 protein level in the hippocampus within a few hours post training, suggesting the role of MMP-3-induced ECM remodeling in associative memory consolidation [<xref ref-type="bibr" rid="CR134">134</xref>]. Habituation increases MMP-3 expression in hippocampus and PFC [<xref ref-type="bibr" rid="CR135">135</xref>], while injection of MMP-3 inhibitor into the hippocampus interferes with this task [<xref ref-type="bibr" rid="CR136">136</xref>].</p>
<p id="Par75">Looking closer into cellular mechanisms of MMP-3 action in the hippocampus, it was reported that, similarly to MMP-9, a transient activation of MMP-3 (within 30 min window post stimulation) is necessary for synaptic potentiation, described in the excitatory postsynaptic potential (EPSP)-to-spike potentiation phenomenon—a long-term potentiation of synaptic inputs [<xref ref-type="bibr" rid="CR137">137</xref>]. EPSP-to-spike potentiation is a NMDA receptor-dependent process and the timing of MMP-3 activation overlaps with the short window of NMDARs activity requirement to prolong the potentiation [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. MMP-3 has been shown to cleave NR1 subunit of NMDA receptors in in vitro neuronal cultures, therefore, it could affect synaptic NMDARs function, necessary during plastic adaptations [<xref ref-type="bibr" rid="CR139">139</xref>]. Moreover, MMP-3 can affect synaptic efficacy by mediating the structural plasticity of dendritic spines. As reported in the visual cortex of MMP-3 KO mice, the morphology of dendritic spines was impaired, namely, the higher number of short, mature spines perturbed open-eye potentiation in visual cortex of these knockout mice [<xref ref-type="bibr" rid="CR140">140</xref>].</p>
<p id="Par76">Similarly to MMP-3, MMP-7 has also been shown to affect spine morphology in a NMDAR-dependent manner. In cultured hippocampal neurons, application of recombinant MMP-7 induced a robust reorganization of spines, changing mushroom-shaped spines into filopodial type. This effect was triggered by rapid F-actin reorganization (observed after 10–20 min) and was dependent on NMDAR function (blocked by MK-801) [<xref ref-type="bibr" rid="CR122">122</xref>]. In fact, in acute cortical slices, MMP-7 cleaved NR1 and NR2A subunits of NMDARs. This caused a reduction in NMDA-induced Ca<sup>2+</sup> influx [<xref ref-type="bibr" rid="CR79">79</xref>]. Therefore, MMP-7 may directly affect NMDARs function and its downstream signaling, pivotal for synaptic plasticity. Moreover, in the presynaptic terminus, application of recombinant MMP-7 on cultured hippocampal neurons decreased the readily releasable pool of synaptic vesicles, decreased the size of active zones and inhibited vesicle recycling [<xref ref-type="bibr" rid="CR78">78</xref>]. MMP-7 effects on vesicle recycling could be partially explained by its cleavage of the SAP-25 protein (synaptosomal-associated protein of 25 kDa), which disrupts the vesicle docking complex [<xref ref-type="bibr" rid="CR78">78</xref>].</p>
<p id="Par77">Among MT-MMPs involved in synaptic functions in the brain, MT5-MMP (MMP-24) is the best characterized. In comparison to other MMPs, it is highly expressed in the brain and it is present at the synapses thanks to binding to AMPA receptor binding protein (ABP), and glutamate receptor interacting protein (GRIP) [<xref ref-type="bibr" rid="CR141">141</xref>]. Monea and co-workers [<xref ref-type="bibr" rid="CR141">141</xref>] have also identified N-cadherins as MT5-MMP substrates, which further implies the important function of this MMP at the synapse. Additionally, MT5-MMP is capable of cleaving β-amyloid precursor protein (APP) creating carboxy-terminal fragments of APP, which are able to impair hippocampal LTP as well as reduce neuronal activity in vivo [<xref ref-type="bibr" rid="CR142">142</xref>]. In a study of traumatic brain injury (TBI) MT5-MMP protein level was increased during synaptic remodeling after the injury and blocking MMPs activity restored levels of N-cadherin and partially restored LTP induction [<xref ref-type="bibr" rid="CR143">143</xref>]. In those experiments MT5-MMP was, however, expressed mainly in reactive astrocytes and applications of GM 6001, a broad spectrum MMP inhibitor, could not exclude the involvement of other MMPs in this process.</p>
</sec>
<sec id="Sec4">
<title>MMPs in epilepsy and epileptogenesis</title>
<p id="Par78">Epilepsy is a brain disorder characterized by an enduring predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological and social consequences of this condition. It is also manifested in the structural changes observed in epileptic brain, such as neuronal reorganization, especially prominent within hippocampus, including axonal sprouting.</p>
<p id="Par79">In fact, epilepsy is not a homogenous disorder, but rather a collection of subtypes with a variety of etiologies. Thus, epilepsies are divided based on the underlying etiology into: (1) genetic, which are caused by genetic factors; (2) structural/metabolic, which have distinct structural or metabolic conditions, including acquired epilepsies caused by stroke or brain trauma; and, (3) of unknown cause [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. Acquired epilepsies constitute about 30% of all cases of epilepsy and are most commonly caused by stroke, brain trauma, alcohol use, neurodegenerative diseases, or infection [<xref ref-type="bibr" rid="CR146">146</xref>]. In acquired epilepsies, brain-damaging insult leads to epileptogenesis (latency period without seizure) lasting up to several years that culminates in the appearance of seizures and epilepsy diagnosis.</p>
<p id="Par80">Among epilepsy types with not well-defined genetic causes, particularly common are temporal lobe epilepsy (TLE) and post-traumatic epilepsy (PTE). TLE is the most frequent and drug-resistant type of adult focal epilepsy, characterized by the appearance of epileptic foci in such temporal lobe structures as hippocampus or amygdala [<xref ref-type="bibr" rid="CR147">147</xref>–<xref ref-type="bibr" rid="CR149">149</xref>]. PTE develops often as a result of TBI caused by an external mechanical force. This initial brain insult triggers a cascade of events called epileptogenesis that can last in humans for years and that finally leads to the appearance of spontaneous recurring seizures (epilepsy) [<xref ref-type="bibr" rid="CR150">150</xref>].</p>
<p id="Par81">There are several mechanisms by which MMPs may participate in epileptogenesis and epilepsy, including blood–brain barrier breakdown, and contributions to inflammatory reactions and synaptic plasticity. The best examined proteinase with a significant role in different models and types of epilepsy appears to be MMP-9 [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR151">151</xref>].</p>
<p id="Par82">Zhang et al. [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>] were the first to report that MMP-9 level (as well as MMP-2) increased in a brain region- and age-related manner in rats subjected to proconvulsive treatment with kainic acid (KA)—a well-recognized model of TLE. Similar increases were also observed after treatment with bicuculline (GABA<sub>A</sub> receptor antagonist, provoking seizures). Next, Szklarczyk et al. [<xref ref-type="bibr" rid="CR47">47</xref>] demonstrated that MMP-9 expression—at the levels of mRNA, protein and enzymatic activity—was markedly upregulated by KA. Of particular interest was surprising finding that those responses were limited to the dentate gyrus, i.e., the hippocampal region undergoing the most extensive post-KA plasticity, presumably supporting epileptogenesis. Then, Wilczynski et al. [<xref ref-type="bibr" rid="CR154">154</xref>] directly investigated the role of MMP-9 in two animal models of epileptogenesis, namely, KA-evoked status epilepticus (SE, a condition known to provoke the development of epilepsy) and proconvulsive pentylenetetrazole (PTZ, a GABA<sub>A</sub> receptor antagonist) chemical kindling. They showed that the sensitivity to PTZ kindling was decreased in MMP-9 knockout mice but was increased in transgenic rats with neuronal overexpression of MMP-9. Furthermore, Wilczynski et al. [<xref ref-type="bibr" rid="CR154">154</xref>] demonstrated that MMP-9 deficiency diminished KA-evoked pruning of dendritic spines and decreased aberrant synaptogenesis after mossy fiber sprouting. Finally, they also reported that MMP-9 was associated with excitatory synapses, where both MMP-9 protein levels and enzymatic activity become strongly increased upon seizures. Subsequently, the presumed role of MMP-9 in epileptogenesis was confirmed by Mizoguchi et al. [<xref ref-type="bibr" rid="CR155">155</xref>], who showed enhanced MMP-9 activity and expression in the injured hippocampus in PTZ kindling model. The role of MMP-9 in the development of epilepsy has been also supported by studies with such models of epilepsy as treatment with either pilocarpine or 4-aminopyridine (seizure-inducing drugs), as well as the use of Wistar Albino Glaxo Rijswijk (WAG/Rij) rats that display higher propensity for seizure activity [<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR157">157</xref>].</p>
<p id="Par83">PTE is a life-long complication of TBI [<xref ref-type="bibr" rid="CR158">158</xref>], where seizures are provoked by head injury. Little is known about the mechanisms that lead to post-injury epilepsy development. Based on data from experimental models and human tissue, epilepsy resulting from head injury is associated with various morphological and physiological changes, such as neurodegeneration, myelin and axonal injury, axonal and synaptic plasticity, changes in spine density/morphology, neurogenesis, gliosis, blood–brain-barrier damage, angiogenesis, changes in extracellular matrix and molecular reorganization of ion channels in individual neurons.</p>
<p id="Par84">It has been reported that in fluid percussion injury (FPI) and controlled cortical impact (CCI) models of TBI, tissue level of mRNA and active form of MMP-9 protein, were increased in ipsilateral cortex and hippocampus after injury [<xref ref-type="bibr" rid="CR159">159</xref>–<xref ref-type="bibr" rid="CR162">162</xref>]. This increase was observed during the first-week post-injury [<xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR164">164</xref>]. Besides the upregulation of MMP-9, time-dependent increase of its inhibitor, TIMP-1 mRNA has been observed in ipsilateral cortical areas [<xref ref-type="bibr" rid="CR165">165</xref>]. Unbalance between MMP-9 and TIMP-1 as a result of insult, could induce various structural, cellular and neurochemical changes, such as mossy fiber sprouting, synaptogenesis, changes in expression of β-dystroglycan, BDNF, integrins as well as cell death or neurogenesis. These processes could lead to increased excitability and changes in neuronal circuitry [<xref ref-type="bibr" rid="CR166">166</xref>]. The possible role of MMP-9 in post-TBI consequences was confirmed by finding that MMP-9 KO mice displayed less prominent motor deficits and significantly smaller post-TBI lesion volumes than wild-type siblings [<xref ref-type="bibr" rid="CR164">164</xref>]. Recently, Pijet et al. [<xref ref-type="bibr" rid="CR167">167</xref>] have demonstrated that PTE occurrence is correlated with the size of the lesion upon injury, where the high level of MMP-9 characterized by a large lesion area, predisposes to PTE development, while inhibition of MMP-9, with small lesion volume, protects from PTE. Pijet et al. [<xref ref-type="bibr" rid="CR167">167</xref>] have also shown that MMP-9 deficiency decreased the seizure appearance in a PTE model, whereas overexpression of MMP-9 increased the likelihood of spontaneous seizures.</p>
<p id="Par85">The contribution of MMP-9 to epileptogenesis has further been substantiated by the use of MMP-9 inhibitors. It has been shown that inhibitors of MMP-9 used in status epilepticus animal model, reduced neuronal cell death [<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR169">169</xref>], modified the inflammatory response by suppression of pro-inflammatory cytokines in microglial cells [<xref ref-type="bibr" rid="CR63">63</xref>]. Finally, inhibition of dendritic spines morphological reorganization and severity of seizures induced in kindling model has been observed by Yeghiazaryan et al. [<xref ref-type="bibr" rid="CR170">170</xref>], who proved the supposition that pharmacological inhibition of MMPs might be beneficial by suppressing seizure progression in animal models of epilepsy [<xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR171">171</xref>].</p>
<p id="Par86">In addition, in humans with different types of epilepsy, the occurrence of the seizures is correlated with the elevated levels of MMP-9 in serum or plasma as well as in the cerebrospinal fluid [<xref ref-type="bibr" rid="CR172">172</xref>–<xref ref-type="bibr" rid="CR175">175</xref>]. Similarly, the ratio of MMP-9 to TIMP-1 was increased under epileptic conditions [<xref ref-type="bibr" rid="CR175">175</xref>]. It has been speculated that this phenomenon can promote brain blood barrier damage [<xref ref-type="bibr" rid="CR176">176</xref>], which is correlated with elevated expression of MMP-9 in serum [<xref ref-type="bibr" rid="CR177">177</xref>]. Moreover, studies made on brain surgery tissue revealed increase in MMP-9 level in epileptogenic lesions associated with epileptic conditions such as focal cortical dysplasia (FCD), tuberous sclerosis or TLE [<xref ref-type="bibr" rid="CR178">178</xref>–<xref ref-type="bibr" rid="CR182">182</xref>]. Interestingly, in children with intractable and non-intractable epilepsy, salivary MMP-9 concentration was decreased compared to controls [<xref ref-type="bibr" rid="CR183">183</xref>]. Zybura-Broda et al. [<xref ref-type="bibr" rid="CR182">182</xref>] have investigated epigenetic changes on the <italic>MMP9</italic> gene promoter, finding an increased DNA demethylation in human epileptic tissue as compared to control brain tissue. Notably, the authors have also demonstrated that progressive <italic>Mmp9</italic> gene promoter demethylation accompanied the development of seizure susceptibility in PTZ kindled rats.</p>
<p id="Par87">The role of other MMPs in epilepsy development appears poorly investigated. An expression of MMP-2 in epileptogenesis process has often been examined simultaneously with MMP-9. Delayed increase in MMP-2 activity was observed in animal models of TLE after systemic injection of pilocarpine [<xref ref-type="bibr" rid="CR168">168</xref>] or kainic acid [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. The increase of MMP-2 was less pronounced compared to MMP-9, nevertheless being significant. However, as so far, there is no further data describing the involvement of MMP-2 in epilepsy development. MMP-2 may increase the permeability of the blood–brain barrier which encourage seizures appearance and facilitates epilepsy development [<xref ref-type="bibr" rid="CR184">184</xref>]. Interestingly, MMP-2 serum levels in patients with epilepsy were significantly lower [<xref ref-type="bibr" rid="CR185">185</xref>].</p>
<p id="Par88">In the kainic acid model of TLE, MMP-3 expression was found to be increased [<xref ref-type="bibr" rid="CR186">186</xref>, <xref ref-type="bibr" rid="CR187">187</xref>]. Moreover, in response to TBI, both hippocampal and CSF levels of MMP-3 were elevated [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR188">188</xref>]. In contrast, serum MMP-3 levels in epileptic patients was found to be decreased [<xref ref-type="bibr" rid="CR185">185</xref>]. Elevated expression of hippocampal MMP-3 mRNA and protein after TBI as well as SE was also reported [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR189">189</xref>]. Gorter et al. [<xref ref-type="bibr" rid="CR62">62</xref>] also demonstrated an enhancement in the expression of MMP-2 and MMP-14 induced by SE evoked by electrical stimulation of the hippocampus.</p>
<p id="Par89">Using an unbiased approach of antibody microarrays, Konopka et al. [<xref ref-type="bibr" rid="CR179">179</xref>] found an elevated expression of MMP-1, -2, -8, -10, and -13, in addition to MMP-9, in the epileptic brain tissue from patients with FCD. However, the expression of these proteinases was not as pronounced and/or not as consistent among patients as the expression of MMP-9. Among these other MMPs, especially striking was the upregulation of MMP-2 in adult patients only, but the significance of this finding is presently unclear.</p>
</sec>
<sec id="Sec5">
<title>MMPs in mental disorders: focus on autism spectrum disorders, fragile X syndrome, schizophrenia, bipolar disorder, chronic stress and major depression</title>
<p id="Par90">Mental health is as a state of well-being that enables individuals to realize their abilities, deal with the normal stresses of life and work productively [<xref ref-type="bibr" rid="CR190">190</xref>]. Mental health disorders appear when the homeostasis is lost and abnormalities in thoughts, perceptions, emotions, behavior and relationships with others appear [<xref ref-type="bibr" rid="CR191">191</xref>]. The rise in number of people suffering from mental disorders makes them a topic of considerable and growing research interest [<xref ref-type="bibr" rid="CR190">190</xref>]. Importantly, the neuropsychiatric disorders often share comorbidities, hence it may seem difficult to draw a hard line between particular medical conditions [<xref ref-type="bibr" rid="CR192">192</xref>]. Therefore, it is legitimate to consider that for this reason they also share some aspects of underlying, including molecular, mechanisms. For the purpose of the present review, we shall focus on stress, major depression, bipolar disorder, autism spectrum and schizophrenia– the most common neuropsychiatric disorders. These diseases pose particular research challenges, as they are all difficult to model in experimental animals. In fact, the animal studies usually focus on reproducing and investigating only selective disease symptoms. Fortunately, the very intense effort on human genomics and proteomics has resulted in revealing major categories of possible molecular players underlying the neuropsychiatric conditions. Those categories are often overlapping among those conditions, with the major ones being: inflammatory/immune responses, epigenetics and gene regulation, and finally synaptic plasticity. Considering the fact that MMPs may fall into both inflammatory/immune category and synaptic plasticity and, as it has been well documented for MMP-9 in the brain, may be under very tight, including epigenetic, gene regulation (see above), there is no surprise that MMPs have been implicated, especially MMP-9, by virtue of gene associations and/or protein levels, in neuropsychiatric disorders.</p>
</sec>
<sec id="Sec6">
<title>MMPs in stress and depression</title>
<p id="Par91">Evolutionarily, stress is a response of the organism to a challenge or threat. When working properly in normal life it helps to maintain balance, and in an emergency situation, to survive. A chronic stress, however, is like a continuous emergency mode that can rewire the brain, so it becomes more vulnerable to anxiety or even a major depression (MD) and other health problems.</p>
<sec id="Sec7">
<title>Human data</title>
<p id="Par92"><italic>MMP9</italic> −1562 C/T (C1562T) gene promoter polymorphism is considered as functional, since a C to T substitution results apparently in a loss of binding of a nuclear silencer protein to this region of the <italic>MMP9</italic> gene to produce an increase in transcriptional activity [<xref ref-type="bibr" rid="CR193">193</xref>]. This polymorphism has been found to be associated with depression, with the C/C genotype or C allele increasing the risk of susceptibility to middle age depression and the T allele, on the other, hand reducing the risk [<xref ref-type="bibr" rid="CR194">194</xref>]. The same study also found that in subjects bearing another <italic>MMP9</italic> gene polymorphism of unknown functionality, namely, −1702 T/A, the T/T genotype or T allele led to increase in risk of recurring depressive disorder, whereas the A/A allele led to lower risks. As far as other MMPs are concerned, analysis of <italic>MMP7</italic> −181 A/G gene polymorphism revealed its strong association with higher incidence of recurring depressive disorder. This research also pointed that dual occurrence of C/T C-735T/<italic>MMP2</italic>/genotype and G/G A-181G/<italic>MMP7</italic>/genotype, and, C/T–T/T genotypes of the <italic>MMP2</italic>C-735T and <italic>MMP9</italic>T-1702A polymorphisms, were also associated with increased risks of recurrent depression [<xref ref-type="bibr" rid="CR194">194</xref>].</p>
<p id="Par93">Expression analysis of MMPs revealed that MMP-9 was upregulated in serum upon two stressful stimuli (recall of either an event that frustrated the patient or a mental arithmetic task) in patients with coronary disease [<xref ref-type="bibr" rid="CR195">195</xref>]. In another study, an increased level of MMP-9 was found in the blood of patients with major depression [<xref ref-type="bibr" rid="CR196">196</xref>]. MMP-9 levels were also correlated with the severity of depression and the quality of life of the patients [<xref ref-type="bibr" rid="CR197">197</xref>]. MMP-9 levels were also found associated with several psychological factors linked with depression in a middle-aged population [<xref ref-type="bibr" rid="CR198">198</xref>]. Another interesting observation was that in patients receiving electro convulsive therapy (ECT) as a treatment for depression, the serum levels of MMP-9 decreased significantly in those patients who did not show relapse of depression [<xref ref-type="bibr" rid="CR199">199</xref>]. Interestingly, transcript and protein levels of MMP-2, MMP-9 and TIMP-2 were found to be downregulated in patients with the recurrent depressive disorder as compared to healthy individuals [<xref ref-type="bibr" rid="CR130">130</xref>]. Finally, both mRNA and protein levels of several MMPs (MMP2, MMP-7 and MMP-9) were demonstrated to be higher in patients with MD, when compared to healthy controls [<xref ref-type="bibr" rid="CR200">200</xref>].</p>
</sec>
<sec id="Sec8">
<title>Animal experiments</title>
<p id="Par94">In an animal model of prolonged stress (restrain of a mouse for 6 h per day, repeated for 21 days) that may contribute to depression, proteolytic activity of MMP-9 was shown to be enhanced in CA1 but not in CA3 of the hippocampus [<xref ref-type="bibr" rid="CR106">106</xref>]. This result correlated with impaired social interactions that were reinstated following infusion of MMP inhibitor into the hippocampus [<xref ref-type="bibr" rid="CR106">106</xref>]. Furthermore, Aguayo et al. [<xref ref-type="bibr" rid="CR201">201</xref>] have found that a single stress exposure (2.5 or 24 h restrain) increases MMP-9 levels and activity in the hippocampus.</p>
</sec>
</sec>
<sec id="Sec9">
<title>MMPs in autism spectrum disorders and fragile X syndrome</title>
<p id="Par95">Autism spectrum disorders (ASD) are considered to be neurodevelopmental disorders that affect communication and behavior. They are classified as a “spectrum” as there is varied range of manifestation of the phenotype [<xref ref-type="bibr" rid="CR202">202</xref>].</p>
<sec id="Sec10">
<title>Human data</title>
<p id="Par96">Probably the most extensively studied genetic alteration linked to ASD concerns <italic>FMR1</italic>, encoding fragile X mental retardation protein (FMRP) [<xref ref-type="bibr" rid="CR203">203</xref>]. Missing FMRP produces fragile X syndrome (FXS). Most interestingly, MMP-9 was found to be upregulated in the serum of patients with FXS, and, moreover, minocycline treatment that decreased MMP-9 levels led to clinical improvements in the patients [<xref ref-type="bibr" rid="CR204">204</xref>–<xref ref-type="bibr" rid="CR207">207</xref>]. In parallel, Janusz et al. [<xref ref-type="bibr" rid="CR83">83</xref>] have demonstrated that FMRP controls local, dendritic/synaptic translation of MMP-9 and then Gkogkas et al. [<xref ref-type="bibr" rid="CR208">208</xref>] using <italic>post mortem</italic> brains from FXS patients showed that phosphorylation of the mRNA 5′ cap binding protein, eukaryotic initiation factor 4E (eIF4E), was elevated concomitantly with increased expression of MMP-9 protein. More generally, the analysis of amniotic fluid in patients with ASD showed elevated levels of MMP-9 [<xref ref-type="bibr" rid="CR209">209</xref>]. Increased MMP-9 was also found in postmortem cortex of ASD patients [<xref ref-type="bibr" rid="CR210">210</xref>].</p>
</sec>
<sec id="Sec11">
<title>Animal experiments</title>
<p id="Par97">There are several lines of evidence linking MMP-9 to FXS. This syndrome is well modeled in mice by the knockout (KO) of the FMRP encoding gene (<italic>Fmr1</italic>). In fact, the first link between FXS and MMP-9 was revealed by Bilousova et al. [<xref ref-type="bibr" rid="CR211">211</xref>], who reported increased MMP-9 activity in cultured neurons from Fmr1 KO mice and, furthermore, the disease phenotype of elongated dendritic spines could be rescued by minocycline inhibiting MMP-9 activity. Similarly, another group also showed that inhibiting MMP-9 could rescue the abnormal spine dynamics noted in Fmr1 KO mice [<xref ref-type="bibr" rid="CR212">212</xref>]. Most interestingly, genetic removal of MMP-9 rescued the ASD-like symptoms of Fragile X in Fmr1 KO mice [<xref ref-type="bibr" rid="CR213">213</xref>]. In another study, where abnormally high level of MMP-9 was observed in the auditory cortex of Fmr1 KO mice, genetic deletion of MMP-9 was able to rescue habituation deficits [<xref ref-type="bibr" rid="CR214">214</xref>].</p>
<p id="Par98">Furthermore, pharmacological inhibition of elF4E dependent MMP-9 translation (see above) has been able to reverse symptoms of Fragile X in Fmr1 KO mice [<xref ref-type="bibr" rid="CR208">208</xref>]. In addition, the drug minocycline was able to lower MMP-9 levels in Fmr1 knockout mice, reduced anxiety and rescued Fragile X such as phenotype [<xref ref-type="bibr" rid="CR215">215</xref>]. Interestingly, metformin, a drug used for treating diabetes, has been shown to normalize elF4E phosphorylation and MMP-9 gene expression, and subsequently rescue the core phenotypes of Fmr1 hemizygous mice [<xref ref-type="bibr" rid="CR216">216</xref>].</p>
<p id="Par99">Perineuronal nets (PNN) are assemblies of the extracellular matrix, which cover the interneurons expressing parvalbumin. Abnormalities in PNN have been reported in schizophrenia and Alzheimer’s disease. MMP-9 is considered as a PNN regulator and thus alterations in its levels might result in PNN abnormalities [<xref ref-type="bibr" rid="CR217">217</xref>]. In fact, genetic reduction of MMP-9 levels to wild-type equivalence in Fmr1 KO mice led to the restoration of PNN formation around parvalbumin cells in the auditory cortex and rescued altered sound-driven response phenotype in these mice [<xref ref-type="bibr" rid="CR217">217</xref>].</p>
<p id="Par100">ASD-like-phenotype had also been reported in zinc transporter 3 (ZnT3) KO mice along with increased MMP-9 and BDNF levels—possibly due to perturbed zinc homeostasis. Treatment of these mice with minocycline rescued ASD-like-phenotype and reduced BDNF levels [<xref ref-type="bibr" rid="CR218">218</xref>].</p>
<p id="Par101">Notably, it has been suggested that MMP-9 might serve as a very promising target for drugs to treat ASD and FXS patients [<xref ref-type="bibr" rid="CR219">219</xref>].</p>
</sec>
</sec>
<sec id="Sec12">
<title>MMPs in schizophrenia and bipolar disorder</title>
<p id="Par102">Schizophrenia is a neuropsychiatric disorder affecting 0.5% of the human population [<xref ref-type="bibr" rid="CR220">220</xref>]. The disease is characterized by heterogeneous display of positive symptoms (hallucinations, delusions, and thought disorder), negative symptoms (avolition, restricted affect, poverty of speech, and social withdrawal), and cognitive dysfunction (working memory deficits, executive function, and attentional dysfunction). Schizophrenia onset occurs typically in early adulthood and is usually associated with a lifetime disability. Bipolar disorder (BD) is a major mental disorder with a high risk of suicide [<xref ref-type="bibr" rid="CR221">221</xref>]. BD onset occurs in adolescence [<xref ref-type="bibr" rid="CR222">222</xref>]. The disorder is characterized by mania episodes followed by depressive ones [<xref ref-type="bibr" rid="CR222">222</xref>]. Of note, even though bipolar disorder and schizophrenia are typically considered to be separate diseases entities, in some cases it is difficult to provide a clear separation and these two conditions may be considered as a schizoaffective disorder [<xref ref-type="bibr" rid="CR223">223</xref>].</p>
<sec id="Sec13">
<title>Human data</title>
<p id="Par103"><italic>MMP9</italic> C1562T gene promoter polymorphism has been shown to associate with schizophrenia [<xref ref-type="bibr" rid="CR224">224</xref>, <xref ref-type="bibr" rid="CR225">225</xref>]. An interesting example of gene-schizophrenia association is rs20544 C/T SNP that has been demonstrated to be strongly linked to the disease delusional symptoms [<xref ref-type="bibr" rid="CR226">226</xref>]. This polymorphism is located within <italic>MMP9</italic> 3′UTR mRNA and the authors have also shown that it affects RNA structure and binding to FMRP as well as synaptic MMP-9 availability and morphology of dendritic spines [<xref ref-type="bibr" rid="CR226">226</xref>]. The polymorphism linked to lower MMP-9 synaptic release has been associated with more severe delusional symptoms [<xref ref-type="bibr" rid="CR226">226</xref>]. Recently, Gregor et al. [<xref ref-type="bibr" rid="CR227">227</xref>] have shown that the effects of anti-psychotic treatment, as well as the severity of childhood trauma are highly dependent on the type of MMP-9 gene variations. Thus, the SNP rs13925 was found to result in a reduced risk of developing treatment refractory schizophrenia, particularly in the presence of homozygous recessive genotype [<xref ref-type="bibr" rid="CR227">227</xref>].</p>
<p id="Par104">As far as <italic>MMP3</italic> is concerned its −1171 5A/6A (rs3025058) polymorphism has been associated with schizophrenia [<xref ref-type="bibr" rid="CR228">228</xref>]. In this study in Turkish population, it was found that the 6A/6A and 6A allele frequency was less in patients with schizophrenia, whereas the 5A/5A and 5A allele frequency was more.</p>
<p id="Par105">Measuring the transcript and protein levels of MMPs in schizophrenia has also yielded interesting results. Ali et al. [<xref ref-type="bibr" rid="CR229">229</xref>] reported that in spite of not finding any correlation between <italic>MMP9</italic> −1562C&gt;T SNP and schizophrenia, the levels of MMP-9 were found to be upregulated in serum of schizophrenic patients. An unbiased approach in screening altered levels of plasma proteins in patients with schizophrenia also revealed increased levels of MMP-9 and TIMP-1 [<xref ref-type="bibr" rid="CR196">196</xref>]. Rahimi et al. [<xref ref-type="bibr" rid="CR230">230</xref>] showed that there were no significant differences in the individual levels of MMP-9 and TIMP-1 genes in schizophrenia patients, but the MMP-9/TIMP-1 ratio was significantly altered (see also Ref. [<xref ref-type="bibr" rid="CR231">231</xref>]). Similarly, upregulated MMP-9 serum levels were found to be strongly associated with levels of mature BDNF (MMP-9 aids in the formation of mature BDNF from pro-BDNF) in schizophrenia patients [<xref ref-type="bibr" rid="CR232">232</xref>]. Another independent study confirmed increased MMP-9 activity in the blood of schizophrenia patients [<xref ref-type="bibr" rid="CR233">233</xref>]. Increased MMP-9 serum levels were likewise found to be correlated to oxidative stress in schizophrenia cases [<xref ref-type="bibr" rid="CR234">234</xref>]. Similarly, MMP-9 gene expression in blood mononuclear cells was found to be upregulated in schizophrenia patients who did not undergo treatment. Interestingly, the levels were no longer significantly different after the administration of the treatment [<xref ref-type="bibr" rid="CR235">235</xref>].</p>
<p id="Par106">As in schizophrenia, polymorphisms and changes in the levels of MMPs have been associated with BD. Rybakowski et al. [<xref ref-type="bibr" rid="CR236">236</xref>] originally demonstrated that C1562T <italic>MMP9</italic> polymorphism linked to BD. It was also found that the serum levels of MMP-9 were upregulated in patients with BD both during the acute phase and remission of depression [<xref ref-type="bibr" rid="CR237">237</xref>]. Sodersten et al. [<xref ref-type="bibr" rid="CR238">238</xref>] observed no differences in the level of MMP-9 in patients with BD but found that its levels correlated positively and significantly with mature BDNF levels, what shall be considered in a context of findings suggesting that MMP-9 may cleave pro-BDNF to its mature form.</p>
<p id="Par107">As far as <italic>MMP10</italic> is concerned, individuals suffering from BD with T/T allele of <italic>MMP10</italic> rs486055 (C/T R53K) polymorphism, were reported to have more depressive events than with C/T or C/C alleles [<xref ref-type="bibr" rid="CR239">239</xref>]. Interestingly MMP-7 levels were also shown to be elevated in patients with BD [<xref ref-type="bibr" rid="CR240">240</xref>, <xref ref-type="bibr" rid="CR241">241</xref>].</p>
</sec>
<sec id="Sec14">
<title>Animal experiments</title>
<p id="Par108">Clearly, the cognitive symptoms of schizophrenia appear the easiest to model in animals by studying learning and memory phenomena, which, however, might lead to great oversimplifications. Nevertheless, in this context, it is worthy to recall the aforementioned data linking MMP-9 levels to learning and memory functions (see above). In addition, negative symptoms of the disease are apparently relatively easy to model, however, to dissect those from depressive behaviors might be difficult. The positive symptoms of schizophrenia can be modelled by enhanced hyperlocomotor response to such NMDA receptors antagonists as MK-801. Lepeta et al. [<xref ref-type="bibr" rid="CR226">226</xref>] demonstrated that MMP-9 heterozygous mice display such enhanced hyperlocomotor response to MK-801, thus, this result was in line with the aforementioned clinical data on MMP-9 3′UTR mRNA polymorphism causing lower synaptic MMP-9 levels and linked to enhanced delusional symptoms of the disease [<xref ref-type="bibr" rid="CR226">226</xref>].</p>
</sec>
</sec>
<sec id="Sec15">
<title>MMPs in addiction: alcohol, cocaine, methamphetamine, nicotine</title>
<p id="Par109">Addiction is a condition characterized by compulsive drug use, seeking and other related behaviors, despite knowledge of the negative consequences [<xref ref-type="bibr" rid="CR242">242</xref>]. Even though in many cases substance use is the most common type of addiction, a person is capable of developing an addiction also to other rewarding behaviors, such as gambling, game playing or internet as well [<xref ref-type="bibr" rid="CR243">243</xref>]. Exposure to addictive substances has been shown to create long-lasting alterations in brain function [<xref ref-type="bibr" rid="CR244">244</xref>]. These take place in brain areas and in neuronal circuits involved in appetitive reward learning and memory formation [<xref ref-type="bibr" rid="CR245">245</xref>]. The overlap between molecular processes involved in the former and pharmacological actions of drugs suggest that the key proteins driving learning and memory are also important players in the formation of addiction.</p>
<p id="Par110">The role of MMPs in addiction has recently been reviewed [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR246">246</xref>]. One of the best described MMPs in the context of addiction is MMP-9. Data from human studies indicate that its levels are increased in the hippocampus of cocaine [<xref ref-type="bibr" rid="CR247">247</xref>], heroin [<xref ref-type="bibr" rid="CR248">248</xref>] and alcohol abusers [<xref ref-type="bibr" rid="CR249">249</xref>]. Furthermore, MMP-9 mRNA level is increased in methamphetamine addicts [<xref ref-type="bibr" rid="CR250">250</xref>]. Moreover, in alcohol abusers, polymorphism of the MMP-9 gene producing higher protein expression is more frequent in alcoholics’ families than in control subjects’ families [<xref ref-type="bibr" rid="CR251">251</xref>]. Animal studies revealed the involvement of MMPs in addiction to morphine [<xref ref-type="bibr" rid="CR252">252</xref>], methamphetamine [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR253">253</xref>, <xref ref-type="bibr" rid="CR254">254</xref>], nicotine [<xref ref-type="bibr" rid="CR255">255</xref>], ethanol [<xref ref-type="bibr" rid="CR256">256</xref>–<xref ref-type="bibr" rid="CR258">258</xref>], cocaine [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR259">259</xref>, <xref ref-type="bibr" rid="CR260">260</xref>] and heroin [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
<p id="Par111">MMPs are activated and play functional roles in such particular aspects of addiction, as motivation in mice and human subjects [<xref ref-type="bibr" rid="CR257">257</xref>], rewarding effect [<xref ref-type="bibr" rid="CR254">254</xref>, <xref ref-type="bibr" rid="CR261">261</xref>, <xref ref-type="bibr" rid="CR262">262</xref>] or relapse/reinstatement in rats [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR255">255</xref>, <xref ref-type="bibr" rid="CR259">259</xref>]. Animals devoid of MMP-9 drink as much alcohol as wild-type animals, yet they are impaired in alcohol seeking when access to ethanol is limited (withdrawal) or requires additional effort to obtain it (motivation) [<xref ref-type="bibr" rid="CR257">257</xref>]. Similar alterations were also observed in MMP-2 and MMP-9 deficient mice, which subjected to methamphetamine treatment did not develop sensitization towards this drug [<xref ref-type="bibr" rid="CR254">254</xref>].</p>
<p id="Par112">Some reports indicate that metalloproteinase inhibitors can reduce behavioral correlates of addiction. MMP-2 and MMP-9 inhibitors reduced sensitization and blocked in mice methamphetamine conditioned place preference (CPP), i.e. rewarding effect of drug manifested by time spent in drug-associated chamber [<xref ref-type="bibr" rid="CR261">261</xref>, <xref ref-type="bibr" rid="CR262">262</xref>]. When infused prior to cocaine administration, a broad spectrum MMP inhibitor blocked acquisition of CPP and reduced its reinstatement after a cocaine-priming injection in rats that underwent CPP extinction [<xref ref-type="bibr" rid="CR259">259</xref>]. The same inhibitor, when injected intracerebroventricularly to rats exposed to long-term alcohol vapor self-administration prevented the escalation of alcohol vapor intake during acute withdrawal [<xref ref-type="bibr" rid="CR256">256</xref>]. Similarly, in heroin addiction, MMP inhibition attenuates heroin cue-induced seeking [<xref ref-type="bibr" rid="CR263">263</xref>]. Not surprisingly then, restoring the availability of MMPs reverses these effects, as overexpressing the active form of MMP-9 in the amygdala increased mice motivation towards ethanol self-administration [<xref ref-type="bibr" rid="CR257">257</xref>].</p>
<p id="Par113">As far as the structural and functional plasticity is concerned, Smith et al. [<xref ref-type="bibr" rid="CR50">50</xref>] discovered that extinction and reinstatement of cocaine self-administration causes an increase in spine density, together with the enlargement of spine heads in neurons of the nucleus accumbens, a structure particularly involved in execution of motivated behaviors and addiction [<xref ref-type="bibr" rid="CR264">264</xref>]. This morphological remodeling is associated with MMP-2 and MMP-9 activities and causes strengthening of glutamatergic synapses, measured by the increase in AMPA/NMDA receptors currents ratio. Our studies in the central amygdala, on the other hand, show that high motivation to ethanol self-administration is associated with the enlargement of long and mushroom spines [<xref ref-type="bibr" rid="CR257">257</xref>]. This effect is not observed in MMP-9 KO mice. Moreover, ethanol consumption and subsequent withdrawal change synaptic efficacy by the formation of silent synapses and the reduction of AMPA/NMDA receptors currents ratio. Silent synapses are immature synaptic connections, which appearance signifies enhanced plasticity [<xref ref-type="bibr" rid="CR265">265</xref>]. They are strongly involved in cocaine and morphine addiction [<xref ref-type="bibr" rid="CR266">266</xref>, <xref ref-type="bibr" rid="CR267">267</xref>]. Our observations that MMP-9 activity causes an increase in silent synapse number [<xref ref-type="bibr" rid="CR29">29</xref>], while genetic ablation of MMP-9 prevents their formation [<xref ref-type="bibr" rid="CR257">257</xref>], indicate that the function of this gelatinase is particularly significant in the remodeling of synaptic efficacy.</p>
</sec>
<sec id="Sec16">
<title>Concluding remarks</title>
<p id="Par114">Whereas traditionally, MMPs in the brain used to be considered as enzymes chiefly contributing to a pathological neuronal cell loss occurring in such disorders as various forms of neurodegeneration, stroke, traumatic brain injury, multiple sclerosis, gliomas, etc., the present review offers another look at the brain MMPs. It has been well documented that these enzymes, with MMP-9 serving as a most prominent example (maybe merely because of being the most extensively studied), contribute to learning and memory, as well as such major neuropsychiatric conditions as epilepsy (its development, i.e., epileptogenesis, in particular), schizophrenia, autism spectrum (with particularly strong example of fragile X syndrome), and addiction to various substances of abuse (including alcohol, cocaine, and others), depression, etc. Physiological and pathological synaptic plasticity emerges as a common theme, as far as the mechanisms of all those conditions are concerned. Indeed, the evidence for pivotal role of some MMPs, again MMP-9 in particular, in functional and morphological, physiological and aberrant plasticity of excitatory synapses appears very convincing. The fact that MMP-9 might be locally produced and released at/around those synapses provides further support for this notion. On the other hand, MMPs might be also produced and released by glia and brain-invading leukocytes, fueling a neuroinflammation. To dissect those various activities (including mutual interactions, e.g., during the activation—cleaving off the propeptide—step) of MMPs, their specific expression patterns (cellular origins and time-courses) poses the major research challenge. Addressing this challenge shall advance not only our understanding of the brain in health and disease but may be expected to lead to novel, important disease biomarkers and diagnoses and even new therapies aiming at either inhibiting the enzymes or augmenting their activities. One should not overlook in this context the apparent regulatory and signaling functions of MMPs, their enzymatic nature (particularly amenable for manipulation) and finally, extracellular locus operandi. It has to be finally noted that overlapping substrate specificity of various MMPs poses a great challenge by itself, as far as the development of specific enzyme inhibitors is concerned.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>3′UTR</term>
<def>
<p id="Par2">3′ Untranslated region</p>
</def>
</def-item>
<def-item>
<term>AMPA</term>
<def>
<p id="Par3">α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid</p>
</def>
</def-item>
<def-item>
<term>AMPAR</term>
<def>
<p id="Par4">α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor</p>
</def>
</def-item>
<def-item>
<term>APP</term>
<def>
<p id="Par5">β-Amyloid precursor protein</p>
</def>
</def-item>
<def-item>
<term>ASD</term>
<def>
<p id="Par6">Autism spectrum disorders</p>
</def>
</def-item>
<def-item>
<term>BD</term>
<def>
<p id="Par7">Bipolar disorder</p>
</def>
</def-item>
<def-item>
<term>BDNF</term>
<def>
<p id="Par8">Brain derived neurotrophic factor</p>
</def>
</def-item>
<def-item>
<term>CA1</term>
<def>
<p id="Par9">Cornu Ammonis area 1, subfield of hippocampus</p>
</def>
</def-item>
<def-item>
<term>CA3</term>
<def>
<p id="Par10">Cornu Ammonis area 3, subfield of hippocampus</p>
</def>
</def-item>
<def-item>
<term>CAM</term>
<def>
<p id="Par11">Cell adhesion molecule</p>
</def>
</def-item>
<def-item>
<term>CCI</term>
<def>
<p id="Par12">Controlled cortical impact</p>
</def>
</def-item>
<def-item>
<term>CPP</term>
<def>
<p id="Par13">Conditioned place preference</p>
</def>
</def-item>
<def-item>
<term>ECM</term>
<def>
<p id="Par14">Extracellular matrix</p>
</def>
</def-item>
<def-item>
<term>ECT</term>
<def>
<p id="Par15">Electro-convulsive therapy</p>
</def>
</def-item>
<def-item>
<term>eIF4E</term>
<def>
<p id="Par16">Eukaryotic initiation factor 4E</p>
</def>
</def-item>
<def-item>
<term>EPSP</term>
<def>
<p id="Par17">Excitatory postsynaptic potential</p>
</def>
</def-item>
<def-item>
<term>FCD</term>
<def>
<p id="Par18">Focal cortical dysplasia</p>
</def>
</def-item>
<def-item>
<term>FMRP</term>
<def>
<p id="Par19">Fragile X mental retardation protein</p>
</def>
</def-item>
<def-item>
<term>FPI</term>
<def>
<p id="Par20">Fluid percussion injury</p>
</def>
</def-item>
<def-item>
<term>FXS</term>
<def>
<p id="Par21">Fragile X syndrome</p>
</def>
</def-item>
<def-item>
<term>GABA</term>
<def>
<p id="Par22">γ-Aminobutyric acid</p>
</def>
</def-item>
<def-item>
<term>ICAM-5</term>
<def>
<p id="Par23">Intercellular adhesion molecule-5</p>
</def>
</def-item>
<def-item>
<term>KA</term>
<def>
<p id="Par24">Kainic acid</p>
</def>
</def-item>
<def-item>
<term>KO</term>
<def>
<p id="Par25">Knockout</p>
</def>
</def-item>
<def-item>
<term>LTD</term>
<def>
<p id="Par26">Long-term depression</p>
</def>
</def-item>
<def-item>
<term>LTP</term>
<def>
<p id="Par27">Long-term potentiation</p>
</def>
</def-item>
<def-item>
<term>MD</term>
<def>
<p id="Par28">Major depression</p>
</def>
</def-item>
<def-item>
<term>MMP</term>
<def>
<p id="Par29">Matrix metalloproteinase</p>
</def>
</def-item>
<def-item>
<term>mRNA</term>
<def>
<p id="Par30">Messenger ribonucleic acid</p>
</def>
</def-item>
<def-item>
<term>MT-MMP</term>
<def>
<p id="Par31">Membrane-type MMP</p>
</def>
</def-item>
<def-item>
<term>NAc</term>
<def>
<p id="Par32">Nucleus accumbens</p>
</def>
</def-item>
<def-item>
<term>NGF</term>
<def>
<p id="Par33">Nerve growth factor</p>
</def>
</def-item>
<def-item>
<term>NMDA</term>
<def>
<p id="Par34"><italic>N</italic>-methyl-<sc>d</sc>-aspartate</p>
</def>
</def-item>
<def-item>
<term>NMDAR</term>
<def>
<p id="Par35"><italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor</p>
</def>
</def-item>
<def-item>
<term>PAR1</term>
<def>
<p id="Par36">Protease activated receptor 1</p>
</def>
</def-item>
<def-item>
<term>PFC</term>
<def>
<p id="Par37">Prefrontal cortex</p>
</def>
</def-item>
<def-item>
<term>PNN</term>
<def>
<p id="Par38">Perineuronal nets</p>
</def>
</def-item>
<def-item>
<term>PTE</term>
<def>
<p id="Par39">Post-traumatic epilepsy</p>
</def>
</def-item>
<def-item>
<term>PTZ</term>
<def>
<p id="Par40">Pentylenetetrazole</p>
</def>
</def-item>
<def-item>
<term>SAP-25</term>
<def>
<p id="Par41">Synaptosomal-associated protein of 25 kDa</p>
</def>
</def-item>
<def-item>
<term>SE</term>
<def>
<p id="Par42">Status epilepticus</p>
</def>
</def-item>
<def-item>
<term>TBI</term>
<def>
<p id="Par43">Traumatic brain injury</p>
</def>
</def-item>
<def-item>
<term>TIMP</term>
<def>
<p id="Par44">Tissue inhibitor of metalloproteinases</p>
</def>
</def-item>
<def-item>
<term>TLE</term>
<def>
<p id="Par45">Temporal lobe epilepsy</p>
</def>
</def-item>
<def-item>
<term>tPA</term>
<def>
<p id="Par46">Tissue plasminogen activator</p>
</def>
</def-item>
<def-item>
<term>uPA</term>
<def>
<p id="Par47">Urokinase plasminogen activator</p>
</def>
</def-item>
<def-item>
<term>ZnT3</term>
<def>
<p id="Par48">Zinc transporter 3</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher's Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>The research in Kaczmarek laboratory is supported by the BRAINCITY program, funded by Foundation for Polish Science and financed by the European Union Smart Development Operational Programme [BRAINCITY (MAB/2018/10)].</p>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dityatev</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rusakov</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Molecular signals of plasticity at the tetrapartite synapse</article-title>
<source/>Curr Opin Neurobiol
          <year>2011</year>
<volume>21</volume>
<issue>2</issue>
<fpage>353</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="pmid">21277196</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrer-Ferrer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dityatev</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Shaping synapses by the neural extracellular matrix</article-title>
<source/>Front Neuroanat
          <year>2018</year>
<volume>12</volume>
<fpage>40</fpage>
<pub-id pub-id-type="pmid">29867379</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rivera</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Khrestchatisky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Jaworski</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?</article-title>
<source/>J Neurosci
          <year>2010</year>
<volume>30</volume>
<issue>46</issue>
<fpage>15337</fpage>
<lpage>15357</lpage>
<pub-id pub-id-type="pmid">21084591</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vafadari</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Salamian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>MMP-9 in translation: from molecule to brain physiology, pathology, and therapy</article-title>
<source/>J Neurochem
          <year>2016</year>
<volume>139</volume>
<issue>Suppl 2</issue>
<fpage>91</fpage>
<lpage>114</lpage>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sternlicht</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Werb</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>How matrix metalloproteinases regulate cell behavior</article-title>
<source/>Annu Rev Cell Dev Biol
          <year>2001</year>
<volume>17</volume>
<fpage>463</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="pmid">11687497</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kaul</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kridel</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Strongin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Liddington</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death</article-title>
<source/>Science
          <year>2002</year>
<volume>297</volume>
<issue>5584</issue>
<fpage>1186</fpage>
<lpage>1190</lpage>
<pub-id pub-id-type="pmid">12183632</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gossas</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Danielson</surname>
<given-names>UH</given-names>
</name>
</person-group>
<article-title>Characterization of Ca<sup>2+</sup> interactions with matrix metallopeptidase-12: implications for matrix metallopeptidase regulation</article-title>
<source/>Biochem J
          <year>2006</year>
<volume>398</volume>
<issue>3</issue>
<fpage>393</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="pmid">16737445</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iyer</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Lindsey</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>The history of matrix metalloproteinases: milestones, myths, and misperceptions</article-title>
<source/>Am J Physiol Heart Circ Physiol
          <year>2012</year>
<volume>303</volume>
<issue>8</issue>
<fpage>H919</fpage>
<lpage>H930</lpage>
<pub-id pub-id-type="pmid">22904159</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lapinska-Dzwonek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Szymczak</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinases in the adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections?</article-title>
<source/>EMBO J
          <year>2002</year>
<volume>21</volume>
<issue>24</issue>
<fpage>6643</fpage>
<lpage>6648</lpage>
<pub-id pub-id-type="pmid">12485985</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuzniewska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rejmak</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Jaworski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kalita</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Brain-derived neurotrophic factor induces matrix metalloproteinase 9 expression in neurons via the serum response factor/c-Fos pathway</article-title>
<source/>Mol Cell Biol
          <year>2013</year>
<volume>33</volume>
<issue>11</issue>
<fpage>2149</fpage>
<lpage>2162</lpage>
<pub-id pub-id-type="pmid">23508111</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dziembowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Milek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Janusz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rejmak</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Romanowska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gorkiewicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tiron</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bramham</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Activity-dependent local translation of matrix metalloproteinase-9</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<issue>42</issue>
<fpage>14538</fpage>
<lpage>14547</lpage>
<pub-id pub-id-type="pmid">23077039</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jasińska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miłek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cymerman</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Łęski</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dziembowska</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>miR-132 regulates dendritic spine structure by direct targeting of matrix metalloproteinase 9 mRNA</article-title>
<source/>Mol Neurobiol
          <year>2016</year>
<volume>53</volume>
<issue>7</issue>
<fpage>4701</fpage>
<lpage>4712</lpage>
<pub-id pub-id-type="pmid">26319558</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zybura-Broda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wolder-Gontarek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ambrozek-Latecka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Choros</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bogusz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wilemska-Dziaduszycka</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rylski</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>HuR (Elavl1) and HuB (Elavl2) stabilize matrix metalloproteinase-9 mRNA during seizure-induced Mmp-9 expression in neurons</article-title>
<source/>Front Neurosci
          <year>2018</year>
<volume>12</volume>
<fpage>224</fpage>
<pub-id pub-id-type="pmid">29686606</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sbai</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ferhat</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gueye</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ould-Yahoui</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thiolloy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Charrat</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Charton</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Risso</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Chauvin</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Arsanto</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Khrestchatisky</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Vesicular trafficking and secretion of matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinases-1 in neuronal cells</article-title>
<source/>Mol Cell Neurosci
          <year>2008</year>
<volume>39</volume>
<issue>4</issue>
<fpage>549</fpage>
<lpage>568</lpage>
<pub-id pub-id-type="pmid">18817873</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sbai</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ould-Yahoui</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ferhat</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gueye</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Charrat</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mehanna</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Risso</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Chauvin</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Fenouillet</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Khrestchatisky</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Differential vesicular distribution and trafficking of MMP-2, MMP-9, and their inhibitors in astrocytes</article-title>
<source/>Glia
          <year>2010</year>
<volume>58</volume>
<issue>3</issue>
<fpage>344</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="pmid">19780201</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schnaeker</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Ossig</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dreier</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Oberleithner</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wilhelmi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion</article-title>
<source/>Cancer Res
          <year>2004</year>
<volume>64</volume>
<issue>24</issue>
<fpage>8924</fpage>
<lpage>8931</lpage>
<pub-id pub-id-type="pmid">15604254</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourguignon</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Gunja-Smith</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Cardiff</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells</article-title>
<source/>J Cell Physiol
          <year>1998</year>
<volume>176</volume>
<issue>1</issue>
<fpage>206</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="pmid">9618160</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dzwonek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>CD44: molecular interactions, signaling and functions in the nervous system</article-title>
<source/>Front Cell Neurosci
          <year>2015</year>
<volume>9</volume>
<fpage>175</fpage>
<pub-id pub-id-type="pmid">25999819</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>XQ</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Paller</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>Ganglioside GM3 inhibits matrix metalloproteinase-9 activation and disrupts its association with integrin</article-title>
<source/>J Biol Chem
          <year>2003</year>
<volume>278</volume>
<issue>28</issue>
<fpage>25591</fpage>
<lpage>25599</lpage>
<pub-id pub-id-type="pmid">12724312</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuzner</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Opdenakker</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system</article-title>
<source/>J Neuroimmunol
          <year>1999</year>
<volume>94</volume>
<issue>1–2</issue>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">10376931</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pei</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Furin-dependent intracellular activation of the human stromelysin-3 zymogen</article-title>
<source/>Nature
          <year>1995</year>
<volume>375</volume>
<issue>6528</issue>
<fpage>244</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="pmid">7746327</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Gervasi</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Mobashery</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fridman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2</article-title>
<source/>J Biol Chem
          <year>1997</year>
<volume>272</volume>
<issue>47</issue>
<fpage>29975</fpage>
<lpage>29983</lpage>
<pub-id pub-id-type="pmid">9368077</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomis-Ruth</surname>
<given-names>FX</given-names>
</name>
<name>
<surname>Maskos</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Betz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bergner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nagase</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Brew</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bourenkov</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Bartunik</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bode</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1</article-title>
<source/>Nature
          <year>1997</year>
<volume>389</volume>
<issue>6646</issue>
<fpage>77</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">9288970</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bjorklund</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heikkila</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Koivunen</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion</article-title>
<source/>J Biol Chem
          <year>2004</year>
<volume>279</volume>
<issue>28</issue>
<fpage>29589</fpage>
<lpage>29597</lpage>
<pub-id pub-id-type="pmid">15123665</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruno</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cuello</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2006</year>
<volume>103</volume>
<issue>17</issue>
<fpage>6735</fpage>
<lpage>6740</lpage>
<pub-id pub-id-type="pmid">16618925</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roderfeld</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Graf</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Giese</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Salguero-Palacios</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tschuschner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muller-Newen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Roeb</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Latent MMP-9 is bound to TIMP-1 before secretion</article-title>
<source/>Biol Chem
          <year>2007</year>
<volume>388</volume>
<issue>11</issue>
<fpage>1227</fpage>
<lpage>1234</lpage>
<pub-id pub-id-type="pmid">17976016</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nagase</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases</article-title>
<source/>J Biol Chem
          <year>1995</year>
<volume>270</volume>
<issue>31</issue>
<fpage>18506</fpage>
<lpage>18511</lpage>
<pub-id pub-id-type="pmid">7629179</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantuano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gaultier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gonias</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Campana</surname>
<given-names>WM</given-names>
</name>
</person-group>
<article-title>The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<issue>45</issue>
<fpage>11571</fpage>
<lpage>11582</lpage>
<pub-id pub-id-type="pmid">18987193</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magnowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gorkiewicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wawrzyniak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rutkowska-Wlodarczyk</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wlodarczyk</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Transient ECM protease activity promotes synaptic plasticity</article-title>
<source/>Sci Rep
          <year>2016</year>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Activation of the P2X(7) receptor induces migration of glial cells by inducing cathepsin B degradation of tissue inhibitor of metalloproteinase 1</article-title>
<source/>J Neurochem
          <year>2012</year>
<volume>123</volume>
<issue>5</issue>
<fpage>761</fpage>
<lpage>770</lpage>
<pub-id pub-id-type="pmid">23017058</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Padamsey</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>McGuinness</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bardo</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Reinhart</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hedegaard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Emptage</surname>
<given-names>NJ</given-names>
</name>
</person-group>
<article-title>Activity-dependent exocytosis of lysosomes regulates the structural plasticity of dendritic spines</article-title>
<source/>Neuron
          <year>2017</year>
<volume>93</volume>
<issue>1</issue>
<fpage>132</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="pmid">27989455</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strongin</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bannikov</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Marmer</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>GI</given-names>
</name>
</person-group>
<article-title>Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease</article-title>
<source/>J Biol Chem
          <year>1995</year>
<volume>270</volume>
<issue>10</issue>
<fpage>5331</fpage>
<lpage>5338</lpage>
<pub-id pub-id-type="pmid">7890645</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoegy</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Corcoran</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Stetler-Stevenson</surname>
<given-names>WG</given-names>
</name>
</person-group>
<article-title>Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition</article-title>
<source/>J Biol Chem
          <year>2001</year>
<volume>276</volume>
<issue>5</issue>
<fpage>3203</fpage>
<lpage>3214</lpage>
<pub-id pub-id-type="pmid">11042184</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ries</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Cytokine functions of TIMP-1</article-title>
<source/>Cell Mol Life Sci
          <year>2014</year>
<volume>71</volume>
<issue>4</issue>
<fpage>659</fpage>
<lpage>672</lpage>
<pub-id pub-id-type="pmid">23982756</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thevenard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Verzeaux</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Devy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Etique</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jeanne</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hachet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ferracci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>David</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martiny</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Charpentier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Khrestchatisky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dedieu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Emonard</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Low-density lipoprotein receptor-related protein-1 mediates endocytic clearance of tissue inhibitor of metalloproteinases-1 and promotes its cytokine-like activities</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>7</issue>
<fpage>e103839</fpage>
<pub-id pub-id-type="pmid">25075518</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verzeaux</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Belloy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Thevenard-Devy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Devy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ferracci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Martiny</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dedieu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dauchez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Emonard</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Etique</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Devarenne-Charpentier</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Intrinsic dynamics study identifies two amino acids of TIMP-1 critical for its LRP-1-mediated endocytosis in neurons</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>5375</fpage>
<pub-id pub-id-type="pmid">28710453</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagenstecher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stalder</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Kincaid</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>IL</given-names>
</name>
</person-group>
<article-title>Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states</article-title>
<source/>Am J Pathol
          <year>1998</year>
<volume>152</volume>
<issue>3</issue>
<fpage>729</fpage>
<lpage>741</lpage>
<pub-id pub-id-type="pmid">9502415</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Majerciak</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ajiro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kruhlak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Meyers</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>ZM</given-names>
</name>
</person-group>
<article-title>Cell type- and tissue context-dependent nuclear distribution of human Ago2</article-title>
<source/>J Biol Chem
          <year>2016</year>
<volume>291</volume>
<issue>5</issue>
<fpage>2302</fpage>
<lpage>2309</lpage>
<pub-id pub-id-type="pmid">26699195</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ierusalimsky</surname>
<given-names>VN</given-names>
</name>
<name>
<surname>Balaban</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>Type 1 metalloproteinase is selectively expressed in adult rat brain and can be rapidly up-regulated by kainate</article-title>
<source/>Acta Histochem
          <year>2013</year>
<volume>115</volume>
<issue>8</issue>
<fpage>816</fpage>
<lpage>826</lpage>
<pub-id pub-id-type="pmid">23683405</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenglet</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Montecucco</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mach</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schaller</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gasche</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Copin</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic stroke</article-title>
<source/>Thromb Haemost
          <year>2014</year>
<volume>112</volume>
<issue>2</issue>
<fpage>363</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="pmid">24671655</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leake</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Whateley</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Brain matrix metalloproteinase 1 levels are elevated in Alzheimer’s disease</article-title>
<source/>Neurosci Lett
          <year>2000</year>
<volume>291</volume>
<issue>3</issue>
<fpage>201</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="pmid">10984641</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ahern</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Villapol</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Maguire-Zeiss</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>35497</fpage>
<pub-id pub-id-type="pmid">27762280</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vos</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Sjulson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nath</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McArthur</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Rothstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures</article-title>
<source/>Exp Neurol
          <year>2000</year>
<volume>163</volume>
<issue>2</issue>
<fpage>324</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="pmid">10833306</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valente</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bortolotto</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grilli</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The MMP-1/PAR-1 axis enhances proliferation and neuronal differentiation of adult hippocampal neural progenitor cells</article-title>
<source/>Neural Plast
          <year>2015</year>
<volume>2015</volume>
<fpage>646595</fpage>
<pub-id pub-id-type="pmid">26783471</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Austin</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Covic</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kuliopulos</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteases and PAR1 activation</article-title>
<source/>Blood
          <year>2013</year>
<volume>121</volume>
<issue>3</issue>
<fpage>431</fpage>
<lpage>439</lpage>
<pub-id pub-id-type="pmid">23086754</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dzwonek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rylski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain</article-title>
<source/>FEBS Lett
          <year>2004</year>
<volume>567</volume>
<issue>1</issue>
<fpage>129</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">15165905</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lapinska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rylski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McKay</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus</article-title>
<source/>J Neurosci
          <year>2002</year>
<volume>22</volume>
<issue>3</issue>
<fpage>920</fpage>
<lpage>930</lpage>
<pub-id pub-id-type="pmid">11826121</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aujla</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Huntley</surname>
<given-names>GW</given-names>
</name>
</person-group>
<article-title>Early postnatal expression and localization of matrix metalloproteinases-2 and -9 during establishment of rat hippocampal synaptic circuitry</article-title>
<source/>J Comp Neurol
          <year>2014</year>
<volume>522</volume>
<issue>6</issue>
<fpage>1249</fpage>
<lpage>1263</lpage>
<pub-id pub-id-type="pmid">24114974</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Planas</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Sole</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Justicia</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia</article-title>
<source/>Neurobiol Dis
          <year>2001</year>
<volume>8</volume>
<issue>5</issue>
<fpage>834</fpage>
<lpage>846</lpage>
<pub-id pub-id-type="pmid">11592852</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Kupchik</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Scofield</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Gipson</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Wiggins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Kalivas</surname>
<given-names>PW</given-names>
</name>
</person-group>
<article-title>Synaptic plasticity mediating cocaine relapse requires matrix metalloproteinases</article-title>
<source/>Nat Neurosci
          <year>2014</year>
<volume>17</volume>
<issue>12</issue>
<fpage>1655</fpage>
<lpage>1657</lpage>
<pub-id pub-id-type="pmid">25326689</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaillant</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Didier-Bazes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hutter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Belin</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Thomasset</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum</article-title>
<source/>J Neurosci
          <year>1999</year>
<volume>19</volume>
<issue>12</issue>
<fpage>4994</fpage>
<lpage>5004</lpage>
<pub-id pub-id-type="pmid">10366632</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bednarek</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Clement</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lelievre</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Loron</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Garnotel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gressens</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Ontogeny of MMPs and TIMPs in the murine neocortex</article-title>
<source/>Pediatr Res
          <year>2009</year>
<volume>65</volume>
<issue>3</issue>
<fpage>296</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="pmid">19092727</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muir</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Adcock</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Morgenstern</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>R</given-names>
</name>
<name>
<surname>von Stillfried</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rhodes</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fawcett</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes</article-title>
<source/>Brain Res Mol Brain Res
          <year>2002</year>
<volume>100</volume>
<issue>1–2</issue>
<fpage>103</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="pmid">12008026</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chollet</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Le Diguardher</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hanessian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Charton</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Khrestchatisky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins</article-title>
<source/>Glia
          <year>2006</year>
<volume>54</volume>
<issue>4</issue>
<fpage>272</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="pmid">16845676</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Hove</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lemmens</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Van de Velde</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Verslegers</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moons</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-3 in the central nervous system: a look on the bright side</article-title>
<source/>J Neurochem
          <year>2012</year>
<volume>123</volume>
<issue>2</issue>
<fpage>203</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="pmid">22862420</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Del Bigio</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Jacque</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Localization of proteinase expression in the developing rabbit brain</article-title>
<source/>Brain Res Dev Brain Res
          <year>1995</year>
<volume>86</volume>
<issue>1–2</issue>
<fpage>345</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="pmid">7656427</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiera</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Hove</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dziegiel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Moons</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mozrzymas</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Mechanisms of NMDA receptor- and voltage-gated L-type calcium channel-dependent hippocampal LTP critically rely on proteolysis that is mediated by distinct metalloproteinases</article-title>
<source/>J Neurosci
          <year>2017</year>
<volume>37</volume>
<issue>5</issue>
<fpage>1240</fpage>
<lpage>1256</lpage>
<pub-id pub-id-type="pmid">28069922</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Hove</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Verslegers</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Buyens</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Delorme</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lemmens</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stroobants</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gantois</surname>
<given-names>I</given-names>
</name>
<name>
<surname>D’Hooge</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Moons</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>An aberrant cerebellar development in mice lacking matrix metalloproteinase-3</article-title>
<source/>Mol Neurobiol
          <year>2012</year>
<volume>45</volume>
<issue>1</issue>
<fpage>17</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">22108898</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ulrich</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gerhauser</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Seeliger</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Baumgartner</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Alldinger</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinases and their inhibitors in the developing mouse brain and spinal cord: a reverse transcription quantitative polymerase chain reaction study</article-title>
<source/>Dev Neurosci
          <year>2005</year>
<volume>27</volume>
<issue>6</issue>
<fpage>408</fpage>
<lpage>418</lpage>
<pub-id pub-id-type="pmid">16280637</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meighan</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Meighan</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Choudhury</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Zornes</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity</article-title>
<source/>J Neurochem
          <year>2006</year>
<volume>96</volume>
<issue>5</issue>
<fpage>1227</fpage>
<lpage>1241</lpage>
<pub-id pub-id-type="pmid">16464240</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Meighan</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Holtfreter</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Benoist</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Muhunthan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Habituation of the head-shake response induces changes in brain matrix metalloproteinases-3 (MMP-3) and -9</article-title>
<source/>Behav Brain Res
          <year>2006</year>
<volume>174</volume>
<issue>1</issue>
<fpage>78</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">16916548</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorter</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Van Vliet</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Rauwerda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Breit</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stad</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van Schaik</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vreugdenhil</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Redeker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hendriksen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Aronica</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lopes da Silva</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Wadman</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Dynamic changes of proteases and protease inhibitors revealed by microarray analysis in CA3 and entorhinal cortex during epileptogenesis in the rat</article-title>
<source/>Epilepsia
          <year>2007</year>
<volume>48</volume>
<issue>Suppl 5</issue>
<fpage>53</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">17910582</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woo</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>IY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HS</given-names>
</name>
</person-group>
<article-title>Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia</article-title>
<source/>J Neurochem
          <year>2008</year>
<volume>106</volume>
<issue>2</issue>
<fpage>770</fpage>
<lpage>780</lpage>
<pub-id pub-id-type="pmid">18419763</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witek-Zawada</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Koj</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Regulation of expression of stromyelysin-1 by proinflammatory cytokines in mouse brain astrocytes</article-title>
<source/>J Physiol Pharmacol
          <year>2003</year>
<volume>54</volume>
<issue>4</issue>
<fpage>489</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="pmid">14726605</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Joh</surname>
<given-names>TH</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<issue>14</issue>
<fpage>3701</fpage>
<lpage>3711</lpage>
<pub-id pub-id-type="pmid">15814801</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuno</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yudoh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Aono</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand</article-title>
<source/>J Rheumatol
          <year>2001</year>
<volume>28</volume>
<issue>1</issue>
<fpage>22</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">11196534</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Fillmore</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>Elevation of hippocampal MMP-3 expression and activity during trauma-induced synaptogenesis</article-title>
<source/>Exp Neurol
          <year>2005</year>
<volume>192</volume>
<issue>1</issue>
<fpage>60</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">15698619</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skuljec</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gudi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ulrich</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Frichert</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yildiz</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Pul</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Voss</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Wissel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Baumgartner</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Stangel</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinases and their tissue inhibitors in cuprizone-induced demyelination and remyelination of brain white and gray matter</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2011</year>
<volume>70</volume>
<issue>9</issue>
<fpage>758</fpage>
<lpage>769</lpage>
<pub-id pub-id-type="pmid">21865884</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Comparison of matrix metalloproteinase expression during Wallerian degeneration in the central and peripheral nervous systems</article-title>
<source/>Neuroscience
          <year>2002</year>
<volume>113</volume>
<issue>2</issue>
<fpage>273</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="pmid">12127085</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberts</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Jenne</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Leger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Todd</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Parney</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Doig</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Yong</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>Kubes</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zygun</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>A prospective evaluation of the temporal matrix metalloproteinase response after severe traumatic brain injury in humans</article-title>
<source/>J Neurotrauma
          <year>2013</year>
<volume>30</volume>
<issue>20</issue>
<fpage>1717</fpage>
<lpage>1726</lpage>
<pub-id pub-id-type="pmid">23725031</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rome</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Arsaut</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Taris</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Couillaud</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Loiseau</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>MMP-7 (matrilysin) expression in human brain tumors</article-title>
<source/>Mol Carcinog
          <year>2007</year>
<volume>46</volume>
<issue>6</issue>
<fpage>446</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="pmid">17219436</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anthony</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Matyzak</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Esiri</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>VH</given-names>
</name>
</person-group>
<article-title>Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke</article-title>
<source/>Neuropathol Appl Neurobiol
          <year>1997</year>
<volume>23</volume>
<issue>5</issue>
<fpage>406</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="pmid">9364466</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cossins</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Clements</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Pigott</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Van der Valk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>De Groot</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions</article-title>
<source/>Acta Neuropathol
          <year>1997</year>
<volume>94</volume>
<issue>6</issue>
<fpage>590</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="pmid">9444361</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-7 regulates cleavage of pro-nerve growth factor and is neuroprotective following kainic acid-induced seizures</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<issue>2</issue>
<fpage>703</fpage>
<lpage>712</lpage>
<pub-id pub-id-type="pmid">22238106</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kieseier</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Kiefer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Clements</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Schweitzer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gearing</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>HP</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis</article-title>
<source/>Brain
          <year>1998</year>
<volume>121</volume>
<issue>Pt 1</issue>
<fpage>159</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="pmid">9549496</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
<name>
<surname>McArthur</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Sjulson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wahl</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Irani</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia</article-title>
<source/>Ann Neurol
          <year>1999</year>
<volume>46</volume>
<issue>3</issue>
<fpage>391</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="pmid">10482270</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kermani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Hempstead</surname>
<given-names>BL</given-names>
</name>
</person-group>
<article-title>Regulation of cell survival by secreted proneurotrophins</article-title>
<source/>Science
          <year>2001</year>
<volume>294</volume>
<issue>5548</issue>
<fpage>1945</fpage>
<lpage>1948</lpage>
<pub-id pub-id-type="pmid">11729324</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oyler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>McKay</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gerfen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Cleavage of neuronal synaptosomal-associated protein of 25 kDa by exogenous matrix metalloproteinase-7</article-title>
<source/>J Neurochem
          <year>2007</year>
<volume>102</volume>
<issue>4</issue>
<fpage>1256</fpage>
<lpage>1263</lpage>
<pub-id pub-id-type="pmid">17472697</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ewaleifoh</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Beique</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Knorr</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Haughey</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Malpica</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mattson</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Huganir</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>MMP-7 cleaves the NR1 NMDA receptor subunit and modifies NMDA receptor function</article-title>
<source/>FASEB J
          <year>2008</year>
<volume>22</volume>
<issue>11</issue>
<fpage>3757</fpage>
<lpage>3767</lpage>
<pub-id pub-id-type="pmid">18644839</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milward</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Szklarczyk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Melli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nayak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Deshpande</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fitzsimmons</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hoke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Calabresi</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Cleavage of myelin associated glycoprotein by matrix metalloproteinases</article-title>
<source/>J Neuroimmunol
          <year>2008</year>
<volume>193</volume>
<issue>1–2</issue>
<fpage>140</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="pmid">18063113</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reinhard</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Razak</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>IM</given-names>
</name>
</person-group>
<article-title>A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders</article-title>
<source/>Front Cell Neurosci
          <year>2015</year>
<volume>9</volume>
<fpage>280</fpage>
<pub-id pub-id-type="pmid">26283917</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gawlak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gorkiewicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gorlewicz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Konopacki</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>High resolution in situ zymography reveals matrix metalloproteinase activity at glutamatergic synapses</article-title>
<source/>Neuroscience
          <year>2009</year>
<volume>158</volume>
<issue>1</issue>
<fpage>167</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="pmid">18588950</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janusz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Milek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Perycz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pacini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bagni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dziembowska</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses</article-title>
<source/>J Neurosci
          <year>2013</year>
<volume>33</volume>
<issue>46</issue>
<fpage>18234</fpage>
<lpage>18241</lpage>
<pub-id pub-id-type="pmid">24227732</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szepesi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hosy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ruszczycki</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bijata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pyskaty</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bikbaev</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heine</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Choquet</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wlodarczyk</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Synaptically released matrix metalloproteinase activity in control of structural plasticity and the cell surface distribution of GluA1-AMPA receptors</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>5</issue>
<fpage>e98274</fpage>
<pub-id pub-id-type="pmid">24853857</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langenfurth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rinnenthal</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Vinnakota</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Prinz</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Carlo</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Stadelmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Siffrin</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Peaschke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Endres</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heppner</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Kettenmann</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Membrane-type 1 metalloproteinase is upregulated in microglia/brain macrophages in neurodegenerative and neuroinflammatory diseases</article-title>
<source/>J Neurosci Res
          <year>2014</year>
<volume>92</volume>
<issue>3</issue>
<fpage>275</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="pmid">24323769</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Py</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marchalant</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Charrat</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Checler</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Khrestchatisky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baranger</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer’s disease: evidence for a pro-amyloidogenic role of MT1-MMP</article-title>
<source/>Front Aging Neurosci
          <year>2014</year>
<volume>6</volume>
<fpage>247</fpage>
<pub-id pub-id-type="pmid">25278878</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cazzin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mion</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Caldara</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rimland</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Domenici</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Microarray analysis of cultured rat hippocampal neurons treated with brain derived neurotrophic factor</article-title>
<source/>Mol Biol Rep
          <year>2011</year>
<volume>38</volume>
<issue>2</issue>
<fpage>983</fpage>
<lpage>990</lpage>
<pub-id pub-id-type="pmid">20535563</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Groef</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Andries</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lemmens</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Van Hove</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Moons</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinases in the mouse retina: a comparative study of expression patterns and MMP antibodies</article-title>
<source/>BMC Ophthalmol
          <year>2015</year>
<volume>15</volume>
<fpage>187</fpage>
<pub-id pub-id-type="pmid">26714639</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irwin</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Byers</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Novel odors affect gene expression for cytokines and proteinases in the rat amygdala and hippocampus</article-title>
<source/>Brain Res
          <year>2012</year>
<volume>1489</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">23103411</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaworski</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Developmental regulation of membrane type-5 matrix metalloproteinase (MT5-MMP) expression in the rat nervous system</article-title>
<source/>Brain Res
          <year>2000</year>
<volume>860</volume>
<issue>1–2</issue>
<fpage>174</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="pmid">10727639</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekine-Aizawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hama</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tsubuki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kanai-Azuma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Aizawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Saido</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain-specific MMP highly expressed in cerebellum</article-title>
<source/>Eur J Neurosci
          <year>2001</year>
<volume>13</volume>
<issue>5</issue>
<fpage>935</fpage>
<lpage>948</lpage>
<pub-id pub-id-type="pmid">11264666</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashita-Kinoh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kinoh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Komori</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chiba</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kajita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yana</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Seiki</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons and regulates axonal growth</article-title>
<source/>Cell Growth Differ
          <year>2001</year>
<volume>12</volume>
<issue>11</issue>
<fpage>573</fpage>
<lpage>580</lpage>
<pub-id pub-id-type="pmid">11714638</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sala</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Dendritic spines: the locus of structural and functional plasticity</article-title>
<source/>Physiol Rev
          <year>2014</year>
<volume>94</volume>
<issue>1</issue>
<fpage>141</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="pmid">24382885</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Long-term depression-inducing stimuli promote cleavage of the synaptic adhesion molecule NGL-3 through NMDA receptors, matrix metalloproteinases and presenilin/gamma-secretase</article-title>
<source/>Philos Trans R Soc Lond B Biol Sci
          <year>2014</year>
<volume>369</volume>
<issue>1633</issue>
<fpage>20130158</fpage>
<pub-id pub-id-type="pmid">24298159</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meighan</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Meighan</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Effects of matrix metalloproteinase inhibition on short- and long-term plasticity of schaffer collateral/CA1 synapses</article-title>
<source/>J Neurochem
          <year>2007</year>
<volume>102</volume>
<issue>6</issue>
<fpage>2085</fpage>
<lpage>2096</lpage>
<pub-id pub-id-type="pmid">17587312</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wojtowicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mozrzymas</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Late phase of long-term potentiation in the mossy fiber-CA3 hippocampal pathway is critically dependent on metalloproteinases activity</article-title>
<source/>Hippocampus
          <year>2010</year>
<volume>20</volume>
<issue>8</issue>
<fpage>917</fpage>
<lpage>921</lpage>
<pub-id pub-id-type="pmid">20572195</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaliszewska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bijata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kossut</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Experience-dependent plasticity of the barrel cortex in mice observed with 2-DG brain mapping and c-Fos: effects of MMP-9 KO</article-title>
<source/>Cereb Cortex
          <year>2012</year>
<volume>22</volume>
<issue>9</issue>
<fpage>2160</fpage>
<lpage>2170</lpage>
<pub-id pub-id-type="pmid">22021911</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pielecka-Fortuna</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kalogeraki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fortuna</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Lowel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Optimal level activity of matrix metalloproteinases is critical for adult visual plasticity in the healthy and stroke-affected brain</article-title>
<source/>Elife
          <year>2015</year>
<volume>5</volume>
<fpage>e11290</fpage>
<pub-id pub-id-type="pmid">26609811</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spolidoro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Putignano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Munafo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Maffei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pizzorusso</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Inhibition of matrix metalloproteinases prevents the potentiation of nondeprived-eye responses after monocular deprivation in juvenile rats</article-title>
<source/>Cereb Cortex
          <year>2012</year>
<volume>22</volume>
<issue>3</issue>
<fpage>725</fpage>
<lpage>734</lpage>
<pub-id pub-id-type="pmid">21685398</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dityatev</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schachner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sonderegger</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The dual role of the extracellular matrix in synaptic plasticity and homeostasis</article-title>
<source/>Nat Rev Neurosci
          <year>2010</year>
<volume>11</volume>
<issue>11</issue>
<fpage>735</fpage>
<lpage>746</lpage>
<pub-id pub-id-type="pmid">20944663</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huntley</surname>
<given-names>GW</given-names>
</name>
</person-group>
<article-title>Synaptic circuit remodelling by matrix metalloproteinases in health and disease</article-title>
<source/>Nat Rev Neurosci
          <year>2012</year>
<volume>13</volume>
<issue>11</issue>
<fpage>743</fpage>
<lpage>757</lpage>
<pub-id pub-id-type="pmid">23047773</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michaluk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction</article-title>
<source/>Cell Death Differ
          <year>2007</year>
<volume>14</volume>
<issue>7</issue>
<fpage>1255</fpage>
<lpage>1258</lpage>
<pub-id pub-id-type="pmid">17431423</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsilibary</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tzinia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Radenovic</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stamenkovic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lebitko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mucha</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pawlak</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Frischknecht</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Neural ECM proteases in learning and synaptic plasticity</article-title>
<source/>Prog Brain Res
          <year>2014</year>
<volume>214</volume>
<fpage>135</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="pmid">25410356</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michaluk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kolodziej</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mioduszewska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Dzwonek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jaworski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gorecki</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Ottersen</surname>
<given-names>OP</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity</article-title>
<source/>J Biol Chem
          <year>2007</year>
<volume>282</volume>
<issue>22</issue>
<fpage>16036</fpage>
<lpage>16041</lpage>
<pub-id pub-id-type="pmid">17426029</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peixoto</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Kunz</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mabb</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Philpot</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Ehlers</surname>
<given-names>MD</given-names>
</name>
</person-group>
<article-title>Transsynaptic signaling by activity-dependent cleavage of neuroligin-1</article-title>
<source/>Neuron
          <year>2012</year>
<volume>76</volume>
<issue>2</issue>
<fpage>396</fpage>
<lpage>409</lpage>
<pub-id pub-id-type="pmid">23083741</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Kooij</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Fantin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rejmak</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Grosse</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zanoletti</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ganguly</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kalita</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sandi</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Role for MMP-9 in stress-induced downregulation of nectin-3 in hippocampal CA1 and associated behavioural alterations</article-title>
<source/>Nat Commun
          <year>2014</year>
<volume>5</volume>
<fpage>4995</fpage>
<pub-id pub-id-type="pmid">25232752</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lonskaya</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Szklarczyk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krall</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maguire-Zeiss</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Methamphetamine-associated cleavage of the synaptic adhesion molecule intercellular adhesion molecule-5</article-title>
<source/>J Neurochem
          <year>2011</year>
<volume>118</volume>
<issue>4</issue>
<fpage>521</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="pmid">21166806</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Gahmberg</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Majewska</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Subcellular localization of intercellular adhesion molecule-5 (telencephalin) in the visual cortex is not developmentally regulated in the absence of matrix metalloproteinase-9</article-title>
<source/>J Comp Neurol
          <year>2014</year>
<volume>522</volume>
<issue>3</issue>
<fpage>676</fpage>
<lpage>688</lpage>
<pub-id pub-id-type="pmid">23897576</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bajor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Michaluk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gulyassy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kekesi</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Juhasz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Synaptic cell adhesion molecule-2 and collapsin response mediator protein-2 are novel members of the matrix metalloproteinase-9 degradome</article-title>
<source/>J Neurochem
          <year>2012</year>
<volume>122</volume>
<issue>4</issue>
<fpage>775</fpage>
<lpage>788</lpage>
<pub-id pub-id-type="pmid">22694054</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorkiewicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Szczuraszek</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wyrembek</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Michaluk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mozrzymas</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 reversibly affects the time course of NMDA-induced currents in cultured rat hippocampal neurons</article-title>
<source/>Hippocampus
          <year>2010</year>
<volume>20</volume>
<issue>10</issue>
<fpage>1105</fpage>
<lpage>1108</lpage>
<pub-id pub-id-type="pmid">20043284</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michaluk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mikasova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Groc</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Frischknecht</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Choquet</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling</article-title>
<source/>J Neurosci
          <year>2009</year>
<volume>29</volume>
<issue>18</issue>
<fpage>6007</fpage>
<lpage>6012</lpage>
<pub-id pub-id-type="pmid">19420267</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lonskaya</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Partridge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lalchandani</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vicini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hoe</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Soluble ICAM-5, a product of activity dependent proteolysis, increases mEPSC frequency and dendritic expression of GluA1</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<issue>7</issue>
<fpage>e69136</fpage>
<pub-id pub-id-type="pmid">23844251</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niedringhaus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dzakpasu</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Synaptic potentiation facilitates memory-like attractor dynamics in cultured in vitro hippocampal networks</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<issue>3</issue>
<fpage>e57144</fpage>
<pub-id pub-id-type="pmid">23526935</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niedringhaus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Dzakpasu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>MMPs and soluble ICAM-5 increase neuronal excitability within in vitro networks of hippocampal neurons</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<issue>8</issue>
<fpage>e42631</fpage>
<pub-id pub-id-type="pmid">22912716</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szepesi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Bijata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ruszczycki</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wlodarczyk</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinases regulate the formation of dendritic spine head protrusions during chemically induced long-term potentiation</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<issue>5</issue>
<fpage>e63314</fpage>
<pub-id pub-id-type="pmid">23696812</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bozdagi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kwei</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Huntley</surname>
<given-names>GW</given-names>
</name>
</person-group>
<article-title>In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity</article-title>
<source/>J Neurophysiol
          <year>2007</year>
<volume>98</volume>
<issue>1</issue>
<fpage>334</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="pmid">17493927</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagy</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bozdagi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Matynia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Balcerzyk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okulski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dzwonek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huntley</surname>
<given-names>GW</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory</article-title>
<source/>J Neurosci
          <year>2006</year>
<volume>26</volume>
<issue>7</issue>
<fpage>1923</fpage>
<lpage>1934</lpage>
<pub-id pub-id-type="pmid">16481424</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>XB</given-names>
</name>
<name>
<surname>Bozdagi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Nikitczuk</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>ZW</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Huntley</surname>
<given-names>GW</given-names>
</name>
</person-group>
<article-title>Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2008</year>
<volume>105</volume>
<issue>49</issue>
<fpage>19520</fpage>
<lpage>19525</lpage>
<pub-id pub-id-type="pmid">19047646</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiera</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wozniak</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bajor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mozrzymas</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Maintenance of long-term potentiation in hippocampal mossy fiber-CA3 pathway requires fine-tuned MMP-9 proteolytic activity</article-title>
<source/>Hippocampus
          <year>2013</year>
<volume>23</volume>
<issue>6</issue>
<fpage>529</fpage>
<lpage>543</lpage>
<pub-id pub-id-type="pmid">23418057</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okulski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jay</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Jaworski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Duniec</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dzwonek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Konopacki</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Sanchez-Capelo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex</article-title>
<source/>Biol Psychiatry
          <year>2007</year>
<volume>62</volume>
<issue>4</issue>
<fpage>359</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="pmid">17210139</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorkiewicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Balcerzyk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Knapska</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase 9 (MMP-9) is indispensable for long term potentiation in the central and basal but not in the lateral nucleus of the amygdala</article-title>
<source/>Front Cell Neurosci
          <year>2015</year>
<volume>9</volume>
<fpage>73</fpage>
<pub-id pub-id-type="pmid">25814930</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilousova</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Rusakov</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>IM</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation</article-title>
<source/>J Neurochem
          <year>2006</year>
<volume>97</volume>
<issue>1</issue>
<fpage>44</fpage>
<lpage>56</lpage>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michaluk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wawrzyniak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alot</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Szczot</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wyrembek</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mercik</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Medvedev</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wilczek</surname>
<given-names>E</given-names>
</name>
<name>
<surname>De Roo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zuschratter</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Mozrzymas</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wlodarczyk</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology</article-title>
<source/>J Cell Sci
          <year>2011</year>
<volume>124</volume>
<issue>Pt 19</issue>
<fpage>3369</fpage>
<lpage>3380</lpage>
<pub-id pub-id-type="pmid">21896646</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stefanidakis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Van Lint</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nyman-Huttunen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Libert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Itohara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mishina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rauvala</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gahmberg</surname>
<given-names>CG</given-names>
</name>
</person-group>
<article-title>Activation of NMDA receptors promotes dendritic spine development through MMP-mediated ICAM-5 cleavage</article-title>
<source/>J Cell Biol
          <year>2007</year>
<volume>178</volume>
<issue>4</issue>
<fpage>687</fpage>
<lpage>700</lpage>
<pub-id pub-id-type="pmid">17682049</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rivera</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Timsit</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Canals</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ben-Ari</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Khrestchatisky</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response</article-title>
<source/>J Neurosci
          <year>1997</year>
<volume>17</volume>
<issue>11</issue>
<fpage>4223</fpage>
<lpage>4235</lpage>
<pub-id pub-id-type="pmid">9151739</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knapska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lioudyno</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kiryk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mikosz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gorkiewicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Michaluk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gawlak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chaturvedi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mochol</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Balcerzyk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wojcik</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Reward learning requires activity of matrix metalloproteinase-9 in the central amygdala</article-title>
<source/>J Neurosci
          <year>2013</year>
<volume>33</volume>
<issue>36</issue>
<fpage>14591</fpage>
<lpage>14600</lpage>
<pub-id pub-id-type="pmid">24005309</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Cocking</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Sorg</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Inhibition of matrix metalloproteinase activity disrupts reconsolidation but not consolidation of a fear memory</article-title>
<source/>Neurobiol Learn Mem
          <year>2009</year>
<volume>91</volume>
<issue>1</issue>
<fpage>66</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">18824238</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Inhibition of hippocampal matrix metalloproteinase-3 and -9 disrupts spatial memory</article-title>
<source/>Neural Plast
          <year>2007</year>
<volume>2007</volume>
<fpage>73813</fpage>
<pub-id pub-id-type="pmid">17502908</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bach</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Tzovara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vunder</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Blocking human fear memory with the matrix metalloproteinase inhibitor doxycycline</article-title>
<source/>Mol Psychiatry
          <year>2017</year>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bobinska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Szemraj</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Galecki</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Talarowska</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The role of MMP genes in recurrent depressive disorders and cognitive functions</article-title>
<source/>Acta Neuropsychiatr
          <year>2016</year>
<volume>28</volume>
<issue>4</issue>
<fpage>221</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="pmid">26856768</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hirano</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ishima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kanahara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Niitsu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shiina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yokote</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Murano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hosoda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakazato</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Altered serum level of matrix metalloproteinase-9 and its association with decision-making in eating disorders</article-title>
<source/>Psychiatry Clin Neurosci
          <year>2017</year>
<volume>71</volume>
<issue>2</issue>
<fpage>124</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="pmid">27891714</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rybakowski</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Skibinska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leszczynska-Rodziewicz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 gene modulates prefrontal cognition in bipolar men</article-title>
<source/>Psychiatr Genet
          <year>2009</year>
<volume>19</volume>
<issue>2</issue>
<fpage>108</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">19668117</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregory</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Kippenhan</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Callicott</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Rubinstein</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Mattay</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>KF</given-names>
</name>
</person-group>
<article-title>Sequence variation associated with SLC12A5 gene expression is linked to brain structure and function in healthy adults</article-title>
<source/>Cereb Cortex
          <year>2019</year>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Meighan</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Asay</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Benoist</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Hippocampal MMP-3 elevation is associated with passive avoidance conditioning</article-title>
<source/>Regul Pept
          <year>2008</year>
<volume>146</volume>
<issue>1–3</issue>
<fpage>19</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">17698214</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Meighan</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Wiediger</surname>
<given-names>RV</given-names>
</name>
<name>
<surname>Sorg</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Habituation-induced neural plasticity in the hippocampus and prefrontal cortex mediated by MMP-3</article-title>
<source/>Behav Brain Res
          <year>2009</year>
<volume>203</volume>
<issue>1</issue>
<fpage>27</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">19389428</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiediger</surname>
<given-names>RV</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Influence of dorsal hippocampal lesions and MMP inhibitors on spontaneous recovery following a habituation/classical conditioning head-shake task</article-title>
<source/>Neurobiol Learn Mem
          <year>2009</year>
<volume>92</volume>
<issue>4</issue>
<fpage>504</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="pmid">19573615</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brzdak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wojcicka</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Zareba-Koziol</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Minge</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Henneberger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wlodarczyk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mozrzymas</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Wojtowicz</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Synaptic potentiation at basal and apical dendrites of hippocampal pyramidal neurons involves activation of a distinct set of extracellular and intracellular molecular cues</article-title>
<source/>Cereb Cortex
          <year>2017</year>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wojtowicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mozrzymas</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Matrix metalloprotease activity shapes the magnitude of EPSPs and spike plasticity within the hippocampal CA3 network</article-title>
<source/>Hippocampus
          <year>2014</year>
<volume>24</volume>
<issue>2</issue>
<fpage>135</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="pmid">24115249</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pauly</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ratliff</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pietrowski</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Neugebauer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schlicksupp</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kirsch</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kuhse</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Activity-dependent shedding of the NMDA receptor glycine binding site by matrix metalloproteinase 3: a PUTATIVE mechanism of postsynaptic plasticity</article-title>
<source/>PLoS One
          <year>2008</year>
<volume>3</volume>
<issue>7</issue>
<fpage>e2681</fpage>
<pub-id pub-id-type="pmid">18629001</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aerts</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nys</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Moons</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Arckens</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Altered neuronal architecture and plasticity in the visual cortex of adult MMP-3-deficient mice</article-title>
<source/>Brain Struct Funct
          <year>2015</year>
<volume>220</volume>
<issue>5</issue>
<fpage>2675</fpage>
<lpage>2689</lpage>
<pub-id pub-id-type="pmid">24957860</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monea</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>S</given-names>
</name>
<name>
<surname>DeSouza</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ziff</surname>
<given-names>EB</given-names>
</name>
</person-group>
<article-title>Membrane localization of membrane type 5 matrix metalloproteinase by AMPA receptor binding protein and cleavage of cadherins</article-title>
<source/>J Neurosci
          <year>2006</year>
<volume>26</volume>
<issue>8</issue>
<fpage>2300</fpage>
<lpage>2312</lpage>
<pub-id pub-id-type="pmid">16495457</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willem</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tahirovic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Busche</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Ovsepian</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Chafai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kootar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hornburg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Daria</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hampel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Giudici</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nuscher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wenninger-Weinzierl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kremmer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Heneka</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Thal</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Giedraitis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lannfelt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Livesey</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Meissner</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Herms</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Konnerth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Haass</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>eta-Secretase processing of APP inhibits neuronal activity in the hippocampus</article-title>
<source/>Nature
          <year>2015</year>
<volume>526</volume>
<issue>7573</issue>
<fpage>443</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="pmid">26322584</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warren</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>MT5-MMP, ADAM-10, and N-cadherin act in concert to facilitate synapse reorganization after traumatic brain injury</article-title>
<source/>J Neurotrauma
          <year>2012</year>
<volume>29</volume>
<issue>10</issue>
<fpage>1922</fpage>
<lpage>1940</lpage>
<pub-id pub-id-type="pmid">22489706</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berg</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Towards a modern classification of the epilepsies?</article-title>
<source/>Lancet Neurol
          <year>2010</year>
<volume>9</volume>
<issue>5</issue>
<fpage>459</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="pmid">20227346</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lukasiuk</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Extracellular proteases in epilepsy</article-title>
<source/>Epilepsy Res
          <year>2011</year>
<volume>96</volume>
<issue>3</issue>
<fpage>191</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="pmid">21893397</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hauser</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Beghi</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>First seizure definitions and worldwide incidence and mortality</article-title>
<source/>Epilepsia
          <year>2008</year>
<volume>49</volume>
<issue>Suppl 1</issue>
<fpage>8</fpage>
<lpage>12</lpage>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engel</surname>
<given-names>J</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>Epilepsy: structural or functional?</article-title>
<source/>AJNR Am J Neuroradiol
          <year>1996</year>
<volume>17</volume>
<issue>2</issue>
<fpage>243</fpage>
<lpage>244</lpage>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mikkonen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Soininen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kalvianen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tapiola</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ylinen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vapalahti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Paljarvi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pitkanen</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Remodeling of neuronal circuitries in human temporal lobe epilepsy: increased expression of highly polysialylated neural cell adhesion molecule in the hippocampus and the entorhinal cortex</article-title>
<source/>Ann Neurol
          <year>1998</year>
<volume>44</volume>
<issue>6</issue>
<fpage>923</fpage>
<lpage>934</lpage>
<pub-id pub-id-type="pmid">9851437</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutula</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cascino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cavazos</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Mossy fiber synaptic reorganization in the epileptic human temporal lobe</article-title>
<source/>Ann Neurol
          <year>1989</year>
<volume>26</volume>
<issue>3</issue>
<fpage>321</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="pmid">2508534</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitkanen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lukasiuk</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Mechanisms of epileptogenesis and potential treatment targets</article-title>
<source/>Lancet Neurol
          <year>2011</year>
<volume>10</volume>
<issue>2</issue>
<fpage>173</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="pmid">21256455</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bronisz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kurkowska-Jastrzebska</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase 9 in epilepsy: the role of neuroinflammation in seizure development</article-title>
<source/>Mediat Inflamm
          <year>2016</year>
<volume>2016</volume>
<fpage>7369020</fpage>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Deb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gottschall</surname>
<given-names>PE</given-names>
</name>
</person-group>
<article-title>Regional and differential expression of gelatinases in rat brain after systemic kainic acid or bicuculline administration</article-title>
<source/>Eur J Neurosci
          <year>1998</year>
<volume>10</volume>
<issue>11</issue>
<fpage>3358</fpage>
<lpage>3368</lpage>
<pub-id pub-id-type="pmid">9824449</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Deb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gottschall</surname>
<given-names>PE</given-names>
</name>
</person-group>
<article-title>Regional and age-related expression of gelatinases in the brains of young and old rats after treatment with kainic acid</article-title>
<source/>Neurosci Lett
          <year>2000</year>
<volume>295</volume>
<issue>1–2</issue>
<fpage>9</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">11078924</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Konopacki</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Wilczek</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lasiecka</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gorlewicz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Michaluk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wawrzyniak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Malinowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okulski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kolodziej</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Konopka</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Duniec</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mioduszewska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nikolaev</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Walczak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Owczarek</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gorecki</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Zuschratter</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ottersen</surname>
<given-names>OP</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Important role of matrix metalloproteinase 9 in epileptogenesis</article-title>
<source/>J Cell Biol
          <year>2008</year>
<volume>180</volume>
<issue>5</issue>
<fpage>1021</fpage>
<lpage>1035</lpage>
<pub-id pub-id-type="pmid">18332222</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizoguchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nakade</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tachibana</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ibi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Someya</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Koike</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kamei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nabeshima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Itohara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takuma</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 contributes to kindled seizure development in pentylenetetrazole-treated mice by converting pro-BDNF to mature BDNF in the hippocampus</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<issue>36</issue>
<fpage>12963</fpage>
<lpage>12971</lpage>
<pub-id pub-id-type="pmid">21900575</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>BI</given-names>
</name>
</person-group>
<article-title>The role of MMP-9 in integrin-mediated hippocampal cell death after pilocarpine-induced status epilepticus</article-title>
<source/>Neurobiol Dis
          <year>2009</year>
<volume>36</volume>
<issue>1</issue>
<fpage>169</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="pmid">19631748</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takacs</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nyilas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Szepesi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Baracskay</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Karlsen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rosvold</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bjorkum</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Czurko</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kekesi</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Juhasz</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 activity increased by two different types of epileptic seizures that do not induce neuronal death: a possible role in homeostatic synaptic plasticity</article-title>
<source/>Neurochem Int
          <year>2010</year>
<volume>56</volume>
<issue>6–7</issue>
<fpage>799</fpage>
<lpage>809</lpage>
<pub-id pub-id-type="pmid">20303372</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frey</surname>
<given-names>LC</given-names>
</name>
</person-group>
<article-title>Epidemiology of posttraumatic epilepsy: a critical review</article-title>
<source/>Epilepsia
          <year>2003</year>
<volume>44</volume>
<issue>s10</issue>
<fpage>11</fpage>
<lpage>17</lpage>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falo</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Fillmore</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-3 expression profile differentiates adaptive and maladaptive synaptic plasticity induced by traumatic brain injury</article-title>
<source/>J Neurosci Res
          <year>2006</year>
<volume>84</volume>
<issue>4</issue>
<fpage>768</fpage>
<lpage>781</lpage>
<pub-id pub-id-type="pmid">16862547</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falo</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>Agrin expression during synaptogenesis induced by traumatic brain injury</article-title>
<source/>J Neurotrauma
          <year>2008</year>
<volume>25</volume>
<issue>7</issue>
<fpage>769</fpage>
<lpage>783</lpage>
<pub-id pub-id-type="pmid">18627255</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>JY</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain temperature</article-title>
<source/>J Neurotrauma
          <year>2010</year>
<volume>27</volume>
<issue>6</issue>
<fpage>1059</fpage>
<lpage>1068</lpage>
<pub-id pub-id-type="pmid">20233042</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Truettner</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>OF</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>WD</given-names>
</name>
</person-group>
<article-title>Influence of therapeutic hypothermia on matrix metalloproteinase activity after traumatic brain injury in rats</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2005</year>
<volume>25</volume>
<issue>11</issue>
<fpage>1505</fpage>
<lpage>1516</lpage>
<pub-id pub-id-type="pmid">15959464</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kaneko</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stahl</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>T</given-names>
</name>
<name>
<surname>van Loveren</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sanberg</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Borlongan</surname>
<given-names>CV</given-names>
</name>
</person-group>
<article-title>Quantitative analyses of matrix metalloproteinase activity after traumatic brain injury in adult rats</article-title>
<source/>Brain Res
          <year>2009</year>
<volume>1280</volume>
<fpage>172</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="pmid">19464272</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Asahi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chwang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Moskowitz</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Fini</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>EH</given-names>
</name>
</person-group>
<article-title>Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury</article-title>
<source/>J Neurosci
          <year>2000</year>
<volume>20</volume>
<issue>18</issue>
<fpage>7037</fpage>
<lpage>7042</lpage>
<pub-id pub-id-type="pmid">10995849</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Gertten</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Holmin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mathiesen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nordqvist</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Increases in matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 mRNA after cerebral contusion and depolarisation</article-title>
<source/>J Neurosci Res
          <year>2003</year>
<volume>73</volume>
<issue>6</issue>
<fpage>803</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="pmid">12949906</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizoguchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Roles of matrix metalloproteinases and their targets in epileptogenesis and seizures</article-title>
<source/>Clin Psychopharmacol Neurosci
          <year>2013</year>
<volume>11</volume>
<issue>2</issue>
<fpage>45</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">24023547</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pijet</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stefaniuk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kostrzewska-Ksiezyk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tsilibary</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Tzinia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Elevation of MMP-9 levels promotes epileptogenesis after traumatic brain injury</article-title>
<source/>Mol Neurobiol
          <year>2018</year>
<volume>1</volume>
<fpage>1</fpage>
</element-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoehna</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Uckermann</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Luksch</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Stefovska</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Marzahn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Theil</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gorkiewicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gawlak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ikonomidou</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase 9 regulates cell death following pilocarpine-induced seizures in the developing brain</article-title>
<source/>Neurobiol Dis
          <year>2012</year>
<volume>48</volume>
<issue>3</issue>
<fpage>339</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="pmid">22782080</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jourquin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Decanis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Charton</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hanessian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chollet</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Le Diguardher</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Khrestchatisky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate</article-title>
<source/>Eur J Neurosci
          <year>2003</year>
<volume>18</volume>
<issue>6</issue>
<fpage>1507</fpage>
<lpage>1517</lpage>
<pub-id pub-id-type="pmid">14511330</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeghiazaryan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rutkowska-Wlodarczyk</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Konopka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Melikyan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Korkotian</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Figiel</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>6</issue>
<fpage>e99789</fpage>
<pub-id pub-id-type="pmid">24918931</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>RP</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 may be a potential therapeutic target in epilepsy</article-title>
<source/>Med Hypotheses
          <year>2011</year>
<volume>76</volume>
<issue>2</issue>
<fpage>184</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="pmid">20888701</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leppert</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Leib</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Grygar</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Schaad</surname>
<given-names>UB</given-names>
</name>
<name>
<surname>Hollander</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood–brain barrier damage and neurological sequelae</article-title>
<source/>Clin Infect Dis
          <year>2000</year>
<volume>31</volume>
<issue>1</issue>
<fpage>80</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">10913401</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>ZH</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhe</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>XL</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Disruption of the blood–brain barrier after generalized tonic-clonic seizures correlates with cerebrospinal fluid MMP-9 levels</article-title>
<source/>J Neuroinflammation
          <year>2013</year>
<volume>10</volume>
<fpage>80</fpage>
<pub-id pub-id-type="pmid">23829879</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Helgeland</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gilhus</surname>
<given-names>NE</given-names>
</name>
</person-group>
<article-title>Serum levels of matrix metalloproteinases: implications in clinical neurology</article-title>
<source/>Eur Neurol
          <year>2012</year>
<volume>67</volume>
<issue>2</issue>
<fpage>121</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="pmid">22262194</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suenaga</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ichiyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Isumi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tohyama</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Furukawa</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Roles of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in acute encephalopathy following prolonged febrile seizures</article-title>
<source/>J Neurol Sci
          <year>2008</year>
<volume>266</volume>
<issue>1–2</issue>
<fpage>126</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="pmid">17928006</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ichiyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Morishima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kajimoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matsushige</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Furukawa</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in influenza-associated encephalopathy</article-title>
<source/>Pediatr Infect Dis J
          <year>2007</year>
<volume>26</volume>
<issue>6</issue>
<fpage>542</fpage>
<lpage>544</lpage>
<pub-id pub-id-type="pmid">17529876</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Awasthi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Sahoo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Paliwal</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Rathore</surname>
<given-names>RK</given-names>
</name>
</person-group>
<article-title>T1-weighted dynamic contrast-enhanced MR evaluation of different stages of neurocysticercosis and its relationship with serum MMP-9 expression</article-title>
<source/>AJNR Am J Neuroradiol
          <year>2013</year>
<volume>34</volume>
<issue>5</issue>
<fpage>997</fpage>
<lpage>1003</lpage>
<pub-id pub-id-type="pmid">23179648</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Acar</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tanriover</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Acar</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Demir</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Increased expression of matrix metalloproteinase-9 in patients with temporal lobe epilepsy</article-title>
<source/>Turk Neurosurg
          <year>2015</year>
<volume>25</volume>
<issue>5</issue>
<fpage>749</fpage>
<lpage>756</lpage>
<pub-id pub-id-type="pmid">26442541</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konopka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grajkowska</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ziemianska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Roszkowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Daszkiewicz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rysz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marchel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koperski</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Dzwonek</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 (MMP-9) in human intractable epilepsy caused by focal cortical dysplasia</article-title>
<source/>Epilepsy Res
          <year>2013</year>
<volume>104</volume>
<issue>1–2</issue>
<fpage>45</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">23182966</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>An</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Increased expression of matrix metalloproteinase 9 in cortical lesions from patients with focal cortical dysplasia type IIb and tuberous sclerosis complex</article-title>
<source/>Brain Res
          <year>2012</year>
<volume>1453</volume>
<fpage>46</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">22459050</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quirico-Santos</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nascimento Mello</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Casimiro Gomes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Carvalho</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>de Souza</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Alves-Leon</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Increased metalloprotease activity in the epileptogenic lesion—lobectomy reduces metalloprotease activity and urokinase-type uPAR circulating levels</article-title>
<source/>Brain Res
          <year>2013</year>
<volume>1538</volume>
<fpage>172</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="pmid">24095794</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zybura-Broda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Amborska</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ambrozek-Latecka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wilemska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bogusz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bucko</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Konopka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grajkowska</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Roszkowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marchel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rysz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koperski</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wilczynski</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rylski</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Epigenetics of epileptogenesis-evoked upregulation of matrix metalloproteinase-9 in hippocampus</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<issue>8</issue>
<fpage>e0159745</fpage>
<pub-id pub-id-type="pmid">27505431</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shahar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Attias</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Savulescu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Genizin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gavish</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nagler</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Oxidative stress, metalloproteinase and LDH in children with intractable and non-intractable epilepsy as reflected in salivary analysis</article-title>
<source/>Epilepsy Res
          <year>2014</year>
<volume>108</volume>
<issue>1</issue>
<fpage>117</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="pmid">24219907</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikonomidou</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinases and epileptogenesis</article-title>
<source/>Mol Cell Pediatr
          <year>2014</year>
<volume>1</volume>
<issue>1</issue>
<fpage>6</fpage>
<pub-id pub-id-type="pmid">26567100</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>GQ</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>RZ</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Serum matrix metalloproteinase-2: a potential biomarker for diagnosis of epilepsy</article-title>
<source/>Epilepsy Res
          <year>2016</year>
<volume>122</volume>
<fpage>114</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="pmid">27016865</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Ghrelin attenuates kainic acid-induced neuronal cell death in the mouse hippocampus</article-title>
<source/>J Endocrinol
          <year>2010</year>
<volume>205</volume>
<issue>3</issue>
<fpage>263</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="pmid">20351014</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Penkowa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Florit</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giralt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Quintana</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Molinero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carrasco</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hidalgo</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures</article-title>
<source/>J Neurosci Res
          <year>2005</year>
<volume>79</volume>
<issue>4</issue>
<fpage>522</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="pmid">15614785</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grossetete</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Phelps</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Arko</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yonas</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury</article-title>
<source/>Neurosurgery
          <year>2009</year>
<volume>65</volume>
<issue>4</issue>
<fpage>702</fpage>
<lpage>708</lpage>
<pub-id pub-id-type="pmid">19834375</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorter</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>van Vliet</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Aronica</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Status epilepticus, blood–brain barrier disruption, inflammation, and epileptogenesis</article-title>
<source/>Epilepsy Behav
          <year>2015</year>
<volume>49</volume>
<fpage>13</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">25958228</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<mixed-citation publication-type="other">World Health Organization (2013) Investing in mental health: Evidence for action. WHO Library Cataloguing-in-Publication Data. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mental_health/publications/financing/investing_in_mh_2013/en/">http://www.who.int/mental_health/publications/financing/investing_in_mh_2013/en/</ext-link>. Accessed 5 June 2019</mixed-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stein</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fulford</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Sadler</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Kendler</surname>
<given-names>KS</given-names>
</name>
</person-group>
<article-title>What is a mental/psychiatric disorder? From DSM-IV to DSM-V</article-title>
<source/>Psychol Med
          <year>2010</year>
<volume>40</volume>
<issue>11</issue>
<fpage>1759</fpage>
<lpage>1765</lpage>
<pub-id pub-id-type="pmid">20624327</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brus</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Solanto</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Adult ADHD vs. bipolar disorder in the DSM-5 era: a challenging differentiation for clinicians</article-title>
<source/>J Psychiatr Pract
          <year>2014</year>
<volume>20</volume>
<issue>6</issue>
<fpage>428</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="pmid">25406047</pub-id>
</element-citation>
</ref>
<ref id="CR193">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Henney</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hamsten</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1</article-title>
<source/>Hum Genet
          <year>1999</year>
<volume>105</volume>
<issue>5</issue>
<fpage>418</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="pmid">10598806</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bobinska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Szemraj</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Czarny</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Galecki</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Role of MMP-2, MMP-7, MMP-9 and TIMP-2 in the development of recurrent depressive disorder</article-title>
<source/>J Affect Disord
          <year>2016</year>
<volume>205</volume>
<fpage>119</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="pmid">27434116</pub-id>
</element-citation>
</ref>
<ref id="CR195">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lundberg</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Jonsson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stenmark</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kristenson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jonasson</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Stress-induced release of matrix metalloproteinase-9 in patients with coronary artery disease: the possible influence of cortisol</article-title>
<source/>Psychoneuroendocrinology
          <year>2016</year>
<volume>73</volume>
<fpage>117</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="pmid">27494070</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domenici</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wille</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Tozzi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Prokopenko</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McKeown</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brittain</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rujescu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Giegling</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Turck</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Holsboer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bullmore</surname>
<given-names>ET</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Merlo-Pich</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Muglia</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections</article-title>
<source/>PLoS One
          <year>2010</year>
<volume>5</volume>
<issue>2</issue>
<fpage>e9166</fpage>
<pub-id pub-id-type="pmid">20161799</pub-id>
</element-citation>
</ref>
<ref id="CR197">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Niitsu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakazato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shiraishi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shiina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kanahara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Enohara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<issue>8</issue>
<fpage>e42676</fpage>
<pub-id pub-id-type="pmid">22880079</pub-id>
</element-citation>
</ref>
<ref id="CR198">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garvin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Carstensen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jonasson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kristenson</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Plasma levels of matrix metalloproteinase-9 are independently associated with psychosocial factors in a middle-aged normal population</article-title>
<source/>Psychosom Med
          <year>2009</year>
<volume>71</volume>
<issue>3</issue>
<fpage>292</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="pmid">19196809</pub-id>
</element-citation>
</ref>
<ref id="CR199">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shibasaki</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Takebayashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Itagaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kajitani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Okada-Tsuchioka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yamawaki</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Altered serum levels of matrix metalloproteinase-2, -9 in response to electroconvulsive therapy for mood disorders</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2016</year>
</element-citation>
</ref>
<ref id="CR200">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bobinska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Szemraj</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Czarny</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Galecki</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Expression and activity of metalloproteinases in depression</article-title>
<source/>Med Sci Monit
          <year>2016</year>
<volume>22</volume>
<fpage>1334</fpage>
<lpage>1341</lpage>
<pub-id pub-id-type="pmid">27098106</pub-id>
</element-citation>
</ref>
<ref id="CR201">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguayo</surname>
<given-names>FI</given-names>
</name>
<name>
<surname>Pacheco</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Garcia-Rojo</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Pizarro-Bauerle</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Doberti</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Tejos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Garcia-Perez</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rojas</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Fiedler</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase 9 displays a particular time response to acute stress: variation in its levels and activity distribution in rat hippocampus</article-title>
<source/>ACS Chem Neurosci
          <year>2018</year>
<volume>9</volume>
<issue>5</issue>
<fpage>945</fpage>
<lpage>956</lpage>
<pub-id pub-id-type="pmid">29361213</pub-id>
</element-citation>
</ref>
<ref id="CR202">
<label>202.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>American Psychiatric Association</collab>
</person-group>
<source/>Diagnostic and statistical manual of mental disorders: DSM-5
          <year>2013</year>
<edition>5</edition>
<publisher-loc>Washington, DC</publisher-loc>
<publisher-name>American Psychiatric Association</publisher-name>
</element-citation>
</ref>
<ref id="CR203">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbeduto</surname>
<given-names>L</given-names>
</name>
<name>
<surname>McDuffie</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thurman</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>The fragile X syndrome-autism comorbidity: what do we really know?</article-title>
<source/>Front Genet
          <year>2014</year>
<volume>5</volume>
<fpage>355</fpage>
<pub-id pub-id-type="pmid">25360144</pub-id>
</element-citation>
</ref>
<ref id="CR204">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dziembowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pretto</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Janusz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Leigh</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Gabriel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Durbin-Johnson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>High MMP-9 activity levels in fragile X syndrome are lowered by minocycline</article-title>
<source/>Am J Med Genet A
          <year>2013</year>
<volume>161A</volume>
<issue>8</issue>
<fpage>1897</fpage>
<lpage>1903</lpage>
<pub-id pub-id-type="pmid">23824974</pub-id>
</element-citation>
</ref>
<ref id="CR205">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leigh</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Winarni</surname>
<given-names>TI</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chechi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Polussa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Doucet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome</article-title>
<source/>J Dev Behav Pediatr
          <year>2013</year>
<volume>34</volume>
<issue>3</issue>
<fpage>147</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="pmid">23572165</pub-id>
</element-citation>
</ref>
<ref id="CR206">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paribello</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Folino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tranfaglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>Open-label add-on treatment trial of minocycline in fragile X syndrome</article-title>
<source/>BMC Neurol
          <year>2010</year>
<volume>10</volume>
<fpage>91</fpage>
<pub-id pub-id-type="pmid">20937127</pub-id>
</element-citation>
</ref>
<ref id="CR207">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Leigh</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nanakul</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chechi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Olichney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Electrocortical changes associated with minocycline treatment in fragile X syndrome</article-title>
<source/>J Psychopharmacol
          <year>2013</year>
<volume>27</volume>
<issue>10</issue>
<fpage>956</fpage>
<lpage>963</lpage>
<pub-id pub-id-type="pmid">23981511</pub-id>
</element-citation>
</ref>
<ref id="CR208">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gkogkas</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Khoutorsky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jafarnejad</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Prager-Khoutorsky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giannakas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kaminari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fragkouli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nader</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Konicek</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Tzinia</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Lacaille</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Sonenberg</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes</article-title>
<source/>Cell Rep
          <year>2014</year>
<volume>9</volume>
<issue>5</issue>
<fpage>1742</fpage>
<lpage>1755</lpage>
<pub-id pub-id-type="pmid">25466251</pub-id>
</element-citation>
</ref>
<ref id="CR209">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdallah</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Greaves-Lord</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Norgaard-Pedersen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hougaard</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Grove</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Amniotic fluid MMP-9 and neurotrophins in autism spectrum disorders: an exploratory study</article-title>
<source/>Autism Res
          <year>2012</year>
<volume>5</volume>
<issue>6</issue>
<fpage>428</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="pmid">23008271</pub-id>
</element-citation>
</ref>
<ref id="CR210">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiorentino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sapone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Senger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Camhi</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Kadzielski</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Buie</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Cascella</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fasano</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Blood–brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders</article-title>
<source/>Mol Autism
          <year>2016</year>
<volume>7</volume>
<fpage>49</fpage>
<pub-id pub-id-type="pmid">27957319</pub-id>
</element-citation>
</ref>
<ref id="CR211">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilousova</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Dansie</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ngo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aye</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Charles</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>IM</given-names>
</name>
</person-group>
<article-title>Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model</article-title>
<source/>J Med Genet
          <year>2009</year>
<volume>46</volume>
<issue>2</issue>
<fpage>94</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="pmid">18835858</pub-id>
</element-citation>
</ref>
<ref id="CR212">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagaoka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Takehara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hayashi-Takagi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shirai</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yagishita</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Akagi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ichiki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kasai</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Abnormal intrinsic dynamics of dendritic spines in a fragile X syndrome mouse model in vivo</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>26651</fpage>
<pub-id pub-id-type="pmid">27221801</pub-id>
</element-citation>
</ref>
<ref id="CR213">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sidhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dansie</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Hickmott</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>IM</given-names>
</name>
</person-group>
<article-title>Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model</article-title>
<source/>J Neurosci
          <year>2014</year>
<volume>34</volume>
<issue>30</issue>
<fpage>9867</fpage>
<lpage>9879</lpage>
<pub-id pub-id-type="pmid">25057190</pub-id>
</element-citation>
</ref>
<ref id="CR214">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lovelace</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Reinhard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Sidhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Razak</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome</article-title>
<source/>Neurobiol Dis
          <year>2016</year>
<volume>89</volume>
<fpage>126</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">26850918</pub-id>
</element-citation>
</ref>
<ref id="CR215">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rotschafer</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Trujillo</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Dansie</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Razak</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome</article-title>
<source/>Brain Res
          <year>2012</year>
<volume>1439</volume>
<fpage>7</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">22265702</pub-id>
</element-citation>
</ref>
<ref id="CR216">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gantois</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Khoutorsky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Popic</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aguilar-Valles</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Freemantle</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Pooters</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nagpal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Skalecka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Truong</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Wiebe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Groves</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Jafarnejad</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Chapat</surname>
<given-names>C</given-names>
</name>
<name>
<surname>McCullagh</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Gamache</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nader</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lacaille</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Gkogkas</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Sonenberg</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Metformin ameliorates core deficits in a mouse model of fragile X syndrome</article-title>
<source/>Nat Med
          <year>2017</year>
<volume>23</volume>
<issue>6</issue>
<fpage>674</fpage>
<lpage>677</lpage>
<pub-id pub-id-type="pmid">28504725</pub-id>
</element-citation>
</ref>
<ref id="CR217">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Ethell</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Razak</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>The perineuronal ‘Safety’ net? Perineuronal net abnormalities in neurological disorders</article-title>
<source/>Front Mol Neurosci
          <year>2018</year>
<volume>11</volume>
<fpage>270</fpage>
<pub-id pub-id-type="pmid">30123106</pub-id>
</element-citation>
</ref>
<ref id="CR218">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoo</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>JY</given-names>
</name>
</person-group>
<article-title>Autism phenotypes in ZnT3 null mice: involvement of zinc dyshomeostasis, MMP-9 activation and BDNF upregulation</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>28548</fpage>
<pub-id pub-id-type="pmid">27352957</pub-id>
</element-citation>
</ref>
<ref id="CR219">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castagnola</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bardoni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Maurin</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>The search for an effective therapy to treat fragile X syndrome: dream or reality?</article-title>
<source/>Front Synaptic Neurosci
          <year>2017</year>
<volume>9</volume>
<fpage>15</fpage>
<pub-id pub-id-type="pmid">29163124</pub-id>
</element-citation>
</ref>
<ref id="CR220">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chant</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Welham</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A systematic review of the prevalence of schizophrenia</article-title>
<source/>PLoS Med
          <year>2005</year>
<volume>2</volume>
<issue>5</issue>
<fpage>e141</fpage>
<pub-id pub-id-type="pmid">15916472</pub-id>
</element-citation>
</ref>
<ref id="CR221">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Haddad</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Bipolar disorder</article-title>
<source/>BMJ
          <year>2012</year>
<volume>345</volume>
<fpage>e8508</fpage>
<pub-id pub-id-type="pmid">23271744</pub-id>
</element-citation>
</ref>
<ref id="CR222">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beentjes</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Goossens</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Poslawsky</surname>
<given-names>IE</given-names>
</name>
</person-group>
<article-title>Caregiver burden in bipolar hypomania and mania: a systematic review</article-title>
<source/>Perspect Psychiatr Care
          <year>2012</year>
<volume>48</volume>
<issue>4</issue>
<fpage>187</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="pmid">23005586</pub-id>
</element-citation>
</ref>
<ref id="CR223">
<label>223.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malaspina</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Heckers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tandon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bustillo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barch</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Gaebel</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gur</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Tsuang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van Os</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Schizoaffective disorder in the DSM-5</article-title>
<source/>Schizophr Res
          <year>2013</year>
<volume>150</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">23707642</pub-id>
</element-citation>
</ref>
<ref id="CR224">
<label>224.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rybakowski</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Skibinska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kapelski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia</article-title>
<source/>Schizophr Res
          <year>2009</year>
<volume>109</volume>
<issue>1–3</issue>
<fpage>90</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">19264454</pub-id>
</element-citation>
</ref>
<ref id="CR225">
<label>225.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>H</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>The C(-1562)T polymorphism of matrix metalloproteinase-9 gene is associated with schizophrenia in China</article-title>
<source/>Psychiatry Res
          <year>2011</year>
<volume>190</volume>
<issue>1</issue>
<fpage>163</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="pmid">21620482</pub-id>
</element-citation>
</ref>
<ref id="CR226">
<label>226.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lepeta</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Purzycka</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Pachulska-Wieczorek</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mitjans</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Begemann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vafadari</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bijata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Adamiak</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Ehrenreich</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dziembowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms</article-title>
<source/>EMBO Mol Med
          <year>2017</year>
<volume>9</volume>
<issue>8</issue>
<fpage>1100</fpage>
<lpage>1116</lpage>
<pub-id pub-id-type="pmid">28623238</pub-id>
</element-citation>
</ref>
<ref id="CR227">
<label>227.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGregor</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>O’Connell</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Emsley</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van der Merwe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Warnich</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene variants in a first-episode schizophrenia cohort</article-title>
<source/>Psychiatry Res
          <year>2018</year>
<volume>262</volume>
<fpage>141</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="pmid">29448178</pub-id>
</element-citation>
</ref>
<ref id="CR228">
<label>228.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kucukali</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Aydin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ozkok</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bilge</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Orhan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zengin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kara</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Do schizophrenia and bipolar disorders share a common disease susceptibility variant at the MMP3 gene?</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>2009</year>
<volume>33</volume>
<issue>3</issue>
<fpage>557</fpage>
<lpage>561</lpage>
<pub-id pub-id-type="pmid">19245826</pub-id>
</element-citation>
</ref>
<ref id="CR229">
<label>229.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali</surname>
<given-names>FT</given-names>
</name>
<name>
<surname>Abd El-Azeem</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Hamed</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>MAM</given-names>
</name>
<name>
<surname>Abd Al-Kader</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: pathophysiological and phenotypic implications</article-title>
<source/>Schizophr Res
          <year>2017</year>
<volume>188</volume>
<fpage>98</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">28100419</pub-id>
</element-citation>
</ref>
<ref id="CR230">
<label>230.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahimi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sayad</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moslemi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ghafouri-Fard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Taheri</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients</article-title>
<source/>Metab Brain Dis
          <year>2017</year>
<volume>32</volume>
<issue>5</issue>
<fpage>1537</fpage>
<lpage>1542</lpage>
<pub-id pub-id-type="pmid">28578515</pub-id>
</element-citation>
</ref>
<ref id="CR231">
<label>231.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeffries</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Perkins</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Khadimallah</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Domenici</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Addington</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bearden</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Cadenhead</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Cornblatt</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Mathalon</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>McGlashan</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Seidman</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Tsuang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>Networks of blood proteins in the neuroimmunology of schizophrenia</article-title>
<source/>Transl Psychiatry
          <year>2018</year>
<volume>8</volume>
<issue>1</issue>
<fpage>112</fpage>
<pub-id pub-id-type="pmid">29875399</pub-id>
</element-citation>
</ref>
<ref id="CR232">
<label>232.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ishima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kishi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ohi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fujimoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Umeda-Yano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine</article-title>
<source/>Neurosci Lett
          <year>2013</year>
<volume>556</volume>
<fpage>37</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">24141084</pub-id>
</element-citation>
</ref>
<ref id="CR233">
<label>233.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Chiang</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Tzang</surname>
<given-names>BS</given-names>
</name>
</person-group>
<article-title>Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia</article-title>
<source/>Psychiatry Res
          <year>2011</year>
<volume>187</volume>
<issue>3</issue>
<fpage>341</fpage>
<lpage>346</lpage>
<pub-id pub-id-type="pmid">20510460</pub-id>
</element-citation>
</ref>
<ref id="CR234">
<label>234.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devanarayanan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nandeesha</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kattimani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: a case control study</article-title>
<source/>Clin Chem Lab Med
          <year>2016</year>
<volume>54</volume>
<issue>3</issue>
<fpage>447</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="pmid">26351924</pub-id>
</element-citation>
</ref>
<ref id="CR235">
<label>235.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumarasinghe</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Beveridge</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Gardiner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Yasawardene</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Perera</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mendis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Suriyakumara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schall</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Tooney</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2013</year>
<volume>16</volume>
<issue>7</issue>
<fpage>1483</fpage>
<lpage>1503</lpage>
<pub-id pub-id-type="pmid">23442539</pub-id>
</element-citation>
</ref>
<ref id="CR236">
<label>236.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rybakowski</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Skibinska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leszczynska-Rodziewicz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 gene and bipolar mood disorder</article-title>
<source/>Neuromol Med
          <year>2009</year>
<volume>11</volume>
<issue>2</issue>
<fpage>128</fpage>
<lpage>132</lpage>
</element-citation>
</ref>
<ref id="CR237">
<label>237.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rybakowski</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Remlinger-Molenda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Czech-Kucharska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wojcicka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Michalak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Losy</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression</article-title>
<source/>J Affect Disord
          <year>2013</year>
<volume>146</volume>
<issue>2</issue>
<fpage>286</fpage>
<lpage>289</lpage>
<pub-id pub-id-type="pmid">22858217</pub-id>
</element-citation>
</ref>
<ref id="CR238">
<label>238.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sodersten</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Palsson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ishima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Funa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Landen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Agren</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in mood-stabilized patients with bipolar disorder: a study of two independent cohorts</article-title>
<source/>J Affect Disord
          <year>2014</year>
<volume>160</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">24709015</pub-id>
</element-citation>
</ref>
<ref id="CR239">
<label>239.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drago</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Monti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>De Ronchi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Serretti</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients</article-title>
<source/>Neuropsychobiology
          <year>2014</year>
<volume>69</volume>
<issue>2</issue>
<fpage>76</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">24576976</pub-id>
</element-citation>
</ref>
<ref id="CR240">
<label>240.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Nassan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Kung</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Veldic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Feeder</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Tye</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Biernacka</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders</article-title>
<source/>Transl Psychiatry
          <year>2015</year>
<volume>5</volume>
<fpage>e689</fpage>
<pub-id pub-id-type="pmid">26645624</pub-id>
</element-citation>
</ref>
<ref id="CR241">
<label>241.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nassan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>YF</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Colby</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Feeder</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Veldic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Bond</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Weinshilboum</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Biernacka</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: applications of a proteomic informed genomic approach</article-title>
<source/>J Psychiatr Res
          <year>2017</year>
<volume>95</volume>
<fpage>208</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="pmid">28886448</pub-id>
</element-citation>
</ref>
<ref id="CR242">
<label>242.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>American Psychiatric Association</collab>
</person-group>
<source/>Diagnostic and statistical manual of mental disorders: DSM-IV-TR
          <year>2000</year>
<edition>4</edition>
<publisher-loc>Washington, DC</publisher-loc>
<publisher-name>American Psychiatric Association</publisher-name>
</element-citation>
</ref>
<ref id="CR243">
<label>243.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grant</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Potenza</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Weinstein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gorelick</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Introduction to behavioral addictions</article-title>
<source/>Am J Drug Alcohol Abuse
          <year>2010</year>
<volume>36</volume>
<issue>5</issue>
<fpage>233</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="pmid">20560821</pub-id>
</element-citation>
</ref>
<ref id="CR244">
<label>244.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volkow</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The brain on drugs: from reward to addiction</article-title>
<source/>Cell
          <year>2015</year>
<volume>162</volume>
<issue>4</issue>
<fpage>712</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="pmid">26276628</pub-id>
</element-citation>
</ref>
<ref id="CR245">
<label>245.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torregrossa</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Corlett</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Aberrant learning and memory in addiction</article-title>
<source/>Neurobiol Learn Mem
          <year>2011</year>
<volume>96</volume>
<issue>4</issue>
<fpage>609</fpage>
<lpage>623</lpage>
<pub-id pub-id-type="pmid">21376820</pub-id>
</element-citation>
</ref>
<ref id="CR246">
<label>246.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Scofield</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Kalivas</surname>
<given-names>PW</given-names>
</name>
</person-group>
<article-title>The tetrapartite synapse: extracellular matrix remodeling contributes to corticoaccumbens plasticity underlying drug addiction</article-title>
<source/>Brain Res
          <year>2015</year>
<volume>1628</volume>
<issue>Pt A</issue>
<fpage>29</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">25838241</pub-id>
</element-citation>
</ref>
<ref id="CR247">
<label>247.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mash</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>ffrench-Mullen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Adi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Buck</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pablo</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Gene expression in human hippocampus from cocaine abusers identifies genes which regulate extracellular matrix remodeling</article-title>
<source/>PLoS One
          <year>2007</year>
<volume>2</volume>
<issue>11</issue>
<fpage>e1187</fpage>
<pub-id pub-id-type="pmid">18000554</pub-id>
</element-citation>
</ref>
<ref id="CR248">
<label>248.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovatsi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Batzios</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nikolaou</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fragou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Njau</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tsatsakis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Karakiulakis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Papakonstantinou</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Alterations in serum MMP and TIMP concentrations following chronic heroin abuse</article-title>
<source/>Toxicol Mech Methods
          <year>2013</year>
<volume>23</volume>
<issue>5</issue>
<fpage>377</fpage>
<lpage>381</lpage>
<pub-id pub-id-type="pmid">23256456</pub-id>
</element-citation>
</ref>
<ref id="CR249">
<label>249.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sillanaukee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kalela</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Seppa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hoyhtya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nikkari</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 is elevated in serum of alcohol abusers</article-title>
<source/>Eur J Clin Investig
          <year>2002</year>
<volume>32</volume>
<issue>4</issue>
<fpage>225</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="pmid">11952806</pub-id>
</element-citation>
</ref>
<ref id="CR250">
<label>250.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Michiue</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Molecular pathology of brain matrix metalloproteases, claudin5, and aquaporins in forensic autopsy cases with special regard to methamphetamine intoxication</article-title>
<source/>Int J Legal Med
          <year>2014</year>
<volume>128</volume>
<issue>3</issue>
<fpage>469</fpage>
<lpage>474</lpage>
<pub-id pub-id-type="pmid">24522335</pub-id>
</element-citation>
</ref>
<ref id="CR251">
<label>251.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samochowiec</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grzywacz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bienkowski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Samochowiec</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mierzejewski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Preuss</surname>
<given-names>UW</given-names>
</name>
<name>
<surname>Grochans</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ciechanowicz</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence: family and case control study</article-title>
<source/>Brain Res
          <year>2010</year>
<volume>1327</volume>
<fpage>103</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="pmid">20197064</pub-id>
</element-citation>
</ref>
<ref id="CR252">
<label>252.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kawasaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kobori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fujita-Hamabe</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Mizoguchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nabeshima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tokuyama</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Involvement of matrix metalloproteinase-9 in the development of morphine tolerance</article-title>
<source/>Eur J Pharmacol
          <year>2012</year>
<volume>683</volume>
<issue>1–3</issue>
<fpage>86</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">22445883</pub-id>
</element-citation>
</ref>
<ref id="CR253">
<label>253.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shaikh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fishback</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>RR</given-names>
</name>
</person-group>
<article-title>Relationship between methamphetamine exposure and matrix metalloproteinase 9 expression</article-title>
<source/>NeuroReport
          <year>2008</year>
<volume>19</volume>
<issue>14</issue>
<fpage>1407</fpage>
<lpage>1409</lpage>
<pub-id pub-id-type="pmid">18766021</pub-id>
</element-citation>
</ref>
<ref id="CR254">
<label>254.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizoguchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Niwa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mouri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Noda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nitta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Itohara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Banno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nabeshima</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice</article-title>
<source/>J Neurochem
          <year>2007</year>
<volume>100</volume>
<issue>6</issue>
<fpage>1579</fpage>
<lpage>1588</lpage>
<pub-id pub-id-type="pmid">17348864</pub-id>
</element-citation>
</ref>
<ref id="CR255">
<label>255.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Natarajan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>A role for matrix metalloproteinases in nicotine-induced conditioned place preference and relapse in adolescent female rats</article-title>
<source/>J Exp Neurosci
          <year>2013</year>
<volume>7</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">25157203</pub-id>
</element-citation>
</ref>
<ref id="CR256">
<label>256.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Nealey</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>Plasticity associated with escalated operant ethanol self-administration during acute withdrawal in ethanol-dependent rats requires intact matrix metalloproteinase systems</article-title>
<source/>Neurobiol Learn Mem
          <year>2011</year>
<volume>96</volume>
<issue>2</issue>
<fpage>199</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="pmid">21530666</pub-id>
</element-citation>
</ref>
<ref id="CR257">
<label>257.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefaniuk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beroun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lebitko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Markina</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Leski</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meyza</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grzywacz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Samochowiec</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Samochowiec</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Radwanska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinase-9 and synaptic plasticity in the central amygdala in control of alcohol-seeking behavior</article-title>
<source/>Biol Psychiatry
          <year>2017</year>
<volume>81</volume>
<issue>11</issue>
<fpage>907</fpage>
<lpage>917</lpage>
<pub-id pub-id-type="pmid">28190519</pub-id>
</element-citation>
</ref>
<ref id="CR258">
<label>258.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Masino</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Reichert</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Meighan</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Meighan</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Ethanol-induced impairment of spatial memory and brain matrix metalloproteinases</article-title>
<source/>Brain Res
          <year>2003</year>
<volume>963</volume>
<issue>1–2</issue>
<fpage>252</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="pmid">12560131</pub-id>
</element-citation>
</ref>
<ref id="CR259">
<label>259.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Forquer</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Cocking</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Sorg</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference</article-title>
<source/>Learn Mem
          <year>2007</year>
<volume>14</volume>
<issue>3</issue>
<fpage>214</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="pmid">17353546</pub-id>
</element-citation>
</ref>
<ref id="CR260">
<label>260.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Forquer</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Sorg</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Increase in matrix metalloproteinase-9 levels in the rat medial prefrontal cortex after cocaine reinstatement of conditioned place preference</article-title>
<source/>Synapse
          <year>2008</year>
<volume>62</volume>
<issue>12</issue>
<fpage>886</fpage>
<lpage>889</lpage>
<pub-id pub-id-type="pmid">18792988</pub-id>
</element-citation>
</ref>
<ref id="CR261">
<label>261.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizoguchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mouri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Niwa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Noda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nitta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Itohara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Banno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nabeshima</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Role of matrix metalloproteinase and tissue inhibitor of MMP in methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor down-regulation and dopamine release</article-title>
<source/>J Neurochem
          <year>2007</year>
<volume>102</volume>
<issue>5</issue>
<fpage>1548</fpage>
<lpage>1560</lpage>
<pub-id pub-id-type="pmid">17472698</pub-id>
</element-citation>
</ref>
<ref id="CR262">
<label>262.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizoguchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nabeshima</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Neuropsychotoxicity of abused drugs: involvement of matrix metalloproteinase-2 and -9 and tissue inhibitor of matrix metalloproteinase-2 in methamphetamine-induced behavioral sensitization and reward in rodents</article-title>
<source/>J Pharmacol Sci
          <year>2008</year>
<volume>106</volume>
<issue>1</issue>
<fpage>9</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">18198472</pub-id>
</element-citation>
</ref>
<ref id="CR263">
<label>263.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Oever</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Lubbers</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Goriounova</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Van der Schors</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Loos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Riga</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wiskerke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Binnekade</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stegeman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schoffelmeer</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Mansvelder</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Smit</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>De Vries</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Spijker</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Extracellular matrix plasticity and GABAergic inhibition of prefrontal cortex pyramidal cells facilitates relapse to heroin seeking</article-title>
<source/>Neuropsychopharmacology
          <year>2010</year>
<volume>35</volume>
<issue>10</issue>
<fpage>2120</fpage>
<lpage>2133</lpage>
<pub-id pub-id-type="pmid">20592718</pub-id>
</element-citation>
</ref>
<ref id="CR264">
<label>264.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalivas</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Volkow</surname>
<given-names>ND</given-names>
</name>
</person-group>
<article-title>New medications for drug addiction hiding in glutamatergic neuroplasticity</article-title>
<source/>Mol Psychiatry
          <year>2011</year>
<volume>16</volume>
<issue>10</issue>
<fpage>974</fpage>
<lpage>986</lpage>
<pub-id pub-id-type="pmid">21519339</pub-id>
</element-citation>
</ref>
<ref id="CR265">
<label>265.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hessler</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Malinow</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice</article-title>
<source/>Nature
          <year>1995</year>
<volume>375</volume>
<issue>6530</issue>
<fpage>400</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="pmid">7760933</pub-id>
</element-citation>
</ref>
<ref id="CR266">
<label>266.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Wayman</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Marie</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Sorg</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Schluter</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Zukin</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>In vivo cocaine experience generates silent synapses</article-title>
<source/>Neuron
          <year>2009</year>
<volume>63</volume>
<issue>1</issue>
<fpage>40</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">19607791</pub-id>
</element-citation>
</ref>
<ref id="CR267">
<label>267.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graziane</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Schlüter</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Opposing mechanisms mediate morphine- and cocaine-induced generation of silent synapses</article-title>
<source/>Nat Neurosci
          <year>2016</year>
<volume>19</volume>
<issue>7</issue>
<fpage>915</fpage>
<lpage>925</lpage>
<pub-id pub-id-type="pmid">27239940</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>